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Abstract
Post-traumatic Stress Disorder (PTSD) is a widespread, often debilitating affliction that is only
partially attenuated by current first-line treatment despite its heightened prominence in the
sociopolitical arena. Since individuals with PTSD also experience high rates of depression
comorbidity and resultant suicidality, it is essential that treatment is more holistically effective. A
possible novel intervention, psilocybin-assisted therapy, has shown promising results for the
improvement of depression, addiction, and other disorders; prospectively, when administered
with non-directive therapy, it could prove to be an efficacious intervention for PTSD with
comorbid depression. In the proposed study, there will be two participant groupings: the control
group - low-dose psilocybin - and the treatment group - high-dose psilocybin. Over the span of
about two months with an additional six-month follow-up, participants will undergo two
increasingly scaled dosing sessions in low or high dosage groups and, throughout, will be
measured for PTSD and depression symptom severity. Participants will be measured using the
Clinician Administered PTSD Scale for the DSM-5 (CAPS-5) and Beck-Depression Inventory II
(BDI-II) as primary measures for PTSD and depression. Outcome measures will be taken at
baseline, before and after both dosing sessions, at the end of the two-month study period, and at
six-month follow-up. A t-test will be conducted to measure any significant differences in
symptom scores between the two participant groupings.

“Just as when we come into the world, when we die we are afraid of the unknown. But the fear
is something from within us that has nothing to do with reality. Dying is like being born: just a
change.”
- Isabel Allende, The House of the Spirits
“To savor what is at this very moment, without trying to change it or even describe it.”
- Michael Pollan, How to Change Your Mind

Author’s Statement
Our present day does not defy the cycles of history; although we may refer to
contemporary strife as unprecedented, we repeat the same mistakes and withstand the same
heartsickening consequences that many people already have lifetimes before. We study history to
avoid this repetition, yet still the COVID-19 pandemic mimics the Spanish flu a century ago and
the Russian invasion of Ukraine can be so easily likened to the aggression that precipitated our
two world wars. Despite all of my history education and the lessons I have internalized on how
best to avoid the mistakes of my predecessors, I feel as if it has only just rendered me a more
observant bystander to our collective failure. Powers too large and too integrated sway the tides
of suffering and success for the masses; for the general population, staying afloat is the most
typical agency we get to enact.
For those others who have practiced their agency on behalf of the masses - politicians,
world leaders, the grossly rich - they have acted regardless of all else, all others; selfishness is the
prevailing wind in this maelstrom. Self-interest is a primary motivator for most people - in itself,
it is intrinsic and necessary - but when those with power lean on it steadfastly and become
increasingly more detached from the consequences of their actions, apathy is the result. ‘Care’
has been mechanically extracted from our lives, as we were all siphoned down a disassembly line
[insert *snaps* here]. I see it as my goal to drum up empathy from within myself and eventually
from others; to compensate for the lack of trickle down, I want to push a tide from the
bottom-up. When caught in a whirlpool, you should remain calm, wait for the right moment to
escape the current, and use what you can to stay afloat. We must withstand the current that
pushes against us with calm, care, and poise, push with overwhelming strength but measured

intent when an opportunity arises to push through the tide, and pray that the force is enough to
shift the current and prevent a drenched demise. Then, hopefully, everyone can be provided a life
jacket when they need it most.
That’s where this research comes in. Many have already been deeply scarred by life’s
relentless deluge. An imbalance between the supply and demand of care has left many
individuals to struggle on their own. People with post-traumatic stress disorder (PTSD) veterans, sexual assault victims, refugees, parents, brothers, sisters, children - are in dire need of
empathy and a system that will catch their fall after the system pushed them in the first place.
Leading with love sounds cheesy and is precisely what one would expect out of a paper on
psychedelics, but its potency still abides. This paper explores the grounded methods by which
such a laconic sentiment can become pragmatic and structured, but that does not negate the
sentimentality of its roots and the emotionally meaningful impacts it can have; we could all do
with a little more sentimentality these days. Ultimately, psilocybin could be one of the many
wrenches necessary to, not only halt apathetic works, but build a system grounded in the natural,
the spiritual, and the charitable.
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Introduction
Overview of Research Purpose
Post-traumatic Stress Disorder (PTSD) is both a lived atrocity and a constant nuisance, it
is an assault on one’s calm, it is a despot of the mind and body, and it is ruinous to normal
functioning. The United States Department of Veterans Affairs (USVA) reports a prevalence of
PTSD in about 7% of Americans (Friedman, 2019). In most people, the disorder presents
following exposure or proximal exposure to a trauma in an instance or a series. The symptoms
themselves vary from recurrence of distressful memories to constant hypervigilance; from
distorted memory about the trauma to dissociation (American Psychiatric Association, 2013).
The symptomatology of PTSD is complex and dynamic, but one consistency throughout time
and across definitions is the suffering it brings. Suicidality plagues the PTSD population: suicide
attempts are 5.3 times likelier to occur in individuals with PTSD when compared with a normal
population and controlled for depression and demographic (Gradus, 2018). Even for those who
do not reach the diagnosis for PTSD - subthreshold individuals - the number of PTSD symptoms
is positively associated with rate of suicidal ideation (Marshall et al., 2001).
Research suggests that many of the connections of an average adult human’s 86 billion
neurons can be disrupted by traumatic stress (Abdallah et al., 2017). PTSD is implicated in the
loss of both synaptic connectivity and plasticity, meaning the brain is left in a dysfunctional
stupor. Add in specifically hindered subcortical brain regions, and extreme emotional
dysregulation and constant hypervigilance is the result (Friedman et al., 2021); everything can
suddenly start feeling like a threat. Needless to say, PTSD can cause major damage to one’s
normal brain functioning.
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This disorder is beyond a cause for concern; it is a plague: one widespread through pain
but obfuscated by politics and cultural mores. There are limited pharmaceutical applications for
PTSD; chiefly Selective Serotonin-Reuptake Inhibitors are used, and they tepidly address the
range of symptomatology (Cipriani et al., 2018). Psychotherapy has relatively positive impacts
on symptoms initially, but poorly addresses comorbidity, and individuals who experience the
whole gamut of PTSD symptoms rarely experience broad symptom reduction (Bradley et al.,
2005); many patients who undergo some form of PTSD-focused psychotherapy still experience
lingering disturbances and dysfunction (Bryant et al., 2016).
Although, to date, there are no
randomized

controlled

trials

(RCTs)

testing psilocybin-assisted therapy for
PTSD, there is still some evidence to
support its potential efficacy as an
alternative treatment. The administration
of psilocybin has shown rapid and
sustained antidepressant effects for treatment-resistant depression and unipolar major depressive
disorder (see Figure 1; Carhart-Harris et al., 2016, 2017, 2018; Davis et al., 2021; Griffiths et al.,
2006; Gukasyan et al., 2022). Additionally, psilocybin has been efficacious at reducing the
depression and anxiety around death among terminally-ill patients and has shown potential for
addiction cessation in tobacco- and alcohol-dependent individuals (Bogenschutz et al., 2015;
Daniel & Haberman, 2017; Griffiths et al., 2016; Johnson et al., 2014; Ross et al., 2016).
Reductions in core obsessive-compulsive disorder (OCD) symptoms were also associated with
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psilocybin administration in a small-scale study (Moreno et al., 2006). In total, the research on
psilocybin-assisted therapy is incredibly promising for treating a wide-range of the disordered
experience, but, moreover, psilocybin administration - provided proper screening and attention
paid to set and setting - is safe and feasible for both disordered and healthy individuals
(Carhart-Harris & Goodwin, 2017; Johnson et al., 2018; Lowe et al., 2021; Rucker et al., 2022).
Considerable precautions need to be taken with a vulnerable and distressed population such as
those afflicted with PTSD, yet the care taken by authors of the aforementioned psilocybin
research provides a strong foundation upon which difficult research can be conducted. Psilocybin
is showing a capacity to help a great many people, and it could be a beneficial tool for those with
PTSD who have, for the most part, been thus failed by their treatment.
From Hysterics to Trauma to Treatment: A History of Post-Traumatic Stress Disorder in
the United States
In the field of Psychology, Post-Traumatic Stress Disorder (PTSD) is a relatively young
diagnosis. Only in 1980, with the release of the Third Edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-III; APA), was PTSD substantiated in a Psychological
framing. This unique diagnosis signaled the capacity for trauma to cause disorder; with the
knowledge that external forces had more of a factor to play in the realm of pathology, the
constituents of Psychology sprung into action, initiating new research about trauma and the role
individual differences play in assessing and internalizing it. An important dichotomy established
in the DSM-III between traumatic stressors and normal stressors is hinged on the concept that
certain stressors are too overwhelming for one’s normal faculties of coping to handle. This
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follows the dose-response model of PTSD wherein the greater the stress is in extremity and/or
duration, the more severe the symptoms of PTSD will manifest (McNally, 2003).
With the DSM-III-Revised (1987) and the DSM-IV (1994), PTSD started incorporating a
broader range of symptomatology, although still precedent on a history of trauma. The diagnostic
criteria of the DSM-IV introduced three symptom clusters: intrusive recollections,
avoidant/numbing symptoms, and hyper-arousal symptoms. As well, this version curated the
duration of the disorder and asserted that significant distress or functional impairment must occur
in the diagnosis. Research following this fourth version began to shift the lens away from the
objective aspects of the trauma and towards the subjective factors that influence how one
experiences it. The dose-response model of PTSD struggled to accommodate this new research.
The subjective interpretation and reinterpretation of a trauma figured significantly in symptom
presentation initially and upon recollection; how severe a traumatic memory is remembered was
found to be more heavily dependent on an individual’s present clinical state rather than the
trauma itself (McNally, 2003). Other research began asserting that people are differentially more
predisposed to experiencing an event as traumatic or developing the full-fledged PTSD disorder
based upon different neurobiological, cultural, and cognitive characteristics (Friedman, 2019).
Although these subjective facets are incredibly important to better understanding the roots of
PTSD, they tie in more with the prevention side of PTSD rather than the treatment side, and
therefore present less in the diagnostic criteria of the DSM series.
The DSM-5 (2013) further expanded on the potential symptom presentation, shifting
away from an exclusively fear-based anxiety disorder and recategorizing it into a new bracket:
trauma- or stressor-related disorder. In that, negative cognition and mood as well as disruptive
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behavior became valid presentations of PTSD. The traumatic event no longer had to be directly
experienced by the individual, but could be more vicariously experienced. Recollection of the
traumatic event must be persistently distressing, agoraphobic-like avoidance can crop up, and
hyperarousal, nearing on paranoia, is typically present as well. The DSM-5 is still the current
standard for diagnosis of PTSD, yet the Psychology community is still finding new hairs to split
from their PTSD problem child. Antecedent to the 11th revision of the World Health
Organization's (WHO) International Classification of Diseases (ICD-11), a newer conceptual
dichotomy has arisen in the trauma- and stressor-related diagnostics. The authors seek to separate
the more elaborate symptom presentation that was recognized in the DSM-5 from PTSD alone.
By establishing a distinct disorder - Complex PTSD (CPTSD) - that would include the primary
aspects of PTSD (reexperiencing, avoidance, and sense of threat) but also supplement the newly
assimilated symptoms (affect dysregulation, negative self-concept, and difficulties in
relationships), the obtuseness of the PTSD diagnosis might be curtailed and the individuals who
are either overlooked by or fit poorly within the current diagnosis might be better treated (Brewin
et al., 2017). This proposal contradicts the DSM-5 but also creates a more acute concept within
trauma- and stressor-related disorders. Clearly, PTSD is still being honed. It has a ways to go, but
the present debate is not unfounded. It is just indicative of PTSD’s long and complicated history;
one that has habitually incapacitated and revived the construct to the point that its routine
existence is, fittingly, somewhere between life and death.
Undoubtedly, the Psychology community has done extensive, meticulous work to
understand trauma-based disorders and how they fluctuate across individuals and communities.
For decades, good researchers and therapists have dedicated themselves to remedying the
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debilitation that is PTSD. However, that work could not be done in a vacuum; society and culture
have always had some role to play in the theater of trauma. Following A Short History of PTSD
by Allan V. Horwitz (2018) - a sociologist with a particularly polemic take on Psychology’s
handling of PTSD - the history of Post-Traumatic Stress Disorder (PTSD) can be seen in its
dynamism through a pair of sociopolitical and scientific eyes, as it oscillates between falsehood
and righteousness, internal and external, predisposition and environment. Horwitz provides a
skeptical view of the PTSD diagnostic and recounts a social history in the United States to
substantiate his objections to the present definition of the disorder. This recounting provides a
rather limiting view of treatment and diagnosis for PTSD, but it is valuable in its comprehensive
representation of the history and in providing a realistic view of how complicated PTSD can be
in diagnosis and treatment; if novel treatment is to be developed for a disorder, it should meet
that disorder where it stands currently, not where it should stand.
The chronicling of this history begins in the 19th century, a time in the U.S. when the
wounds of soldiers in the American Civil War and catastrophes of railroad workers were
important steps for social, political, and economic progress. More than 600,000 fatalities were
recorded in the whole of the civil war - a massive loss when taking into account population
inflation. To boot, inexperienced soldiers made up a majority of the Union and Confederate ranks
and therefore were the perpetrators of any brutality between North and South; lost limbs amputated or mauled - deadly infection, and hand-to-hand combat all made for a pretty good
pool of traumatic experiences for the given veteran to draw from later on in life. However neither
PTSD nor trauma were conceptualized or treated as they are now. Nicknames of the time, such as
“combat fatigue,” loosely suggested the presence of some psychiatric concern, but generally
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claims of non-physical impairment were met with skepticism or charged with malingering. In the
case of railroad workers, train traffic became common, and the resultant wrecks did as well.
Many workers found themselves caught in a careening piece of steaming, prototyped metal: the
epitome of uncontrol in the face of imminent death. Following a crash, left with understandably
unhealthy mental states or persistent emotional erraticism, the workers were effectively alone in a
fight with their minds.
The contemporaneous attempts at understanding these ‘new’, stressor-related traumas
were empathetic in intent, flawed in conception, but moderately helpful in outcome. It became
commonplace to misattribute any leftover psychic misnomers rather to the body than the mind.
Civil war veterans began to fall under a diagnosis of “irritable heart,” indicated by some of the
hypervigilant and emotional reactive symptoms that we now associate with PTSD. As for
railroad workers, the misattribution was more dorsal; “railroad spine” became the leading
diagnosis for latent psychic trauma following a train-related accident. This physical ailment separate from hysteria, which carried similar manifestations but was connoted with greater
femininity - was defined as a spinal compression that subsequently dysregulated the usual and
expected emotional stolidity of man; gender proves to be a complicating factor throughout the
history of wartime trauma in that mental trauma is only culturally allotted to the effeminate.
These speculative diagnoses physicalized an apparently more mental disruption, but
nonetheless the product was relatively positive for the disrupted. Prior to a physical diagnosis,
these struggles were ones to be had quietly, insularly, and with the help of alcohol or opiates.
These struggles became liable to the environment rather than the individual and his poor
continence. In turn, they became liable to the powers that precipitated the individual’s exposure

Gomez, 8

to that environment. For the soldiers, this was the U.S. government, mandated to repay in the
form of a pension. For the workers, this was the railway corporations, mandated to repay in the
form of liability compensation.
This is where the history becomes rather financial in nature; the conversation around
mental trauma as a result of life-threatening circumstances shifts in a monetary direction. Not
only is the narrative of malingering perpetuated by a new financial incentive, but the only
solution devised for harmed individuals in the warring countries, as a result of the countries
warring, was a financial one. This then created a paradigm for trauma-denial based around
compensation rather than the previous implication of laziness or cowardice. The ‘traumatic
malingerer’ is a caricature that will appear time and time again in this history, rationalized rather
acrobatically at times. As expected, the persistent, transgressive habits that arose out of soldiers
in the American Civil War also began arising in those of World War I; present in soldiers both
acutely and chronically, a variety of symptoms - some intersecting with PTSD, some not - were
attributed to another body-based ailment called “shell shock”. In this, the physical impact of
artillery shelling resulted in psychosomatic symptoms; over time, this definition bore its latent
trauma, hinging more on the emotional repercussions of the war than the ill-fitting physical
paradigm. Even once the effects of war were generally recognized in the public and clinical eyes,
there was still debate to be had over their causes. If problems these soldiers experienced could be
understood psychogenically - in that, soldiers with predisposed vulnerabilities or weaker
machismos were the only sufferers of mental hangovers - rather than extragenically - in that, any
soldier could suffer mental hangovers of war given the right, or extremely wrong, circumstances
- then the blame could still be deftly placed on the victim.
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The stress of war yet again begot monetary recompense; however, this time pensions
strained a world that was already withstanding the waves of a Great Depression. Alongside the
money came a shadow of moral judgment that began, once again, associating veterans with
laziness and dishonesty. Veteran advocacy groups had managed to elicit federal intervention on
behalf of the psychically harmed, yet this stoked the cultural flame of stigma and created the
possibility of unhealthy monetary dependence for the affected. Just in time, World War II ushered
in a clinical assertion of inevitable psychic neuroses given enough wartime exposure. The official
US report, Combat Exhaustion, following the Second World War laid out clearly that war had the
capacity to take its toll on nearly everyone, with the exceptions being psychopathic outliers
(Bartemeier et al., 1946). Military psychiatrists had been proliferated throughout the frontlines,
charged with providing immediate psychiatric support to the psychically wounded so they could
promptly return to the fighting. Veteran advocacy groups managed to win support broader than
pure pension provisions and, in the US and most of the Western world, the general population
was thriving as a benefit of winning the war. Less attention was paid to war-based neuroses when
there was funding available for veteran programs and the war had been a financial and moral
victory.
The next, and arguably most pivotal, stage in the history of PTSD is its diagnosis; how
the disorder is structured today is informed by its first official recognition in the Third Edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM-III). In this section of the
history, a more diverse perspective is warranted provided the polemic perspective Horwitz takes
on diagnosis itself. With that, Richard J. McNally’s (2003) recounting of the Vietnam War and
the consequent formalization of PTSD into the DSM-III, in his systematic review Progress and

Gomez, 10

Controversy in the Study of Posttraumatic Stress Disorder, will supplement, and occasionally
contradict, Horwitz’s history. Both authors seem to agree on the note that the Vietnam War
precipitated a cultural fervor behind veterans that mismatched to the lived experience of those
veterans. The archetype of the disenfranchised, maltreated Vietnam vet strayed from reality, with
media attempting to illustrate the senselessness of the war through a fictional, pitiful character;
the rate of mental breakdown was far lower in Vietnam fighters than in both Korea and WWII
and there was no evidence of broad mistreatment or felt disdain upon the soldiers’ return home
(Dean, 1997). Regardless, there was a strong push for the standardization of trauma as a result of
the immoral war, and the authors of the DSM-III were forced to contend with the societal affront.
Given that the DSM-III was intended to include only a-causal disorders, ones that were separate
from identity and individual traits, the outcry for trauma-resultant disorder was rather
problematic. Moreover, the DSM authors, somewhat ignorantly, were wary to include disorder
that appeared to be linked with a single historical event (i.e. Vietnam War) rather than something
generalized (McNally, 2003).
Despite these stated goals and apprehensions, in 1980 the authors decided to implement
PTSD into the psychologist’s diagnostic deck of cards. This diagnosis included four main
aspects: the presence of a remarkable stressor from present or past, recurrence of trauma, general
numbing, and experiencing two out of a slew of intractable symptoms indicating overhanging
manifestations of trauma; in addition, a distinction was drawn between acute PTSD and
chronic/delayed PTSD based upon the time before symptoms occur and persist following the
initial trauma (APA, 1980). For better or for worse, the diagnosis was validated and bestowed to
those who could meet the official criteria; the DSM-III sparked a wealth of research into trauma
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as a psychological phenomenon (McNally, 2003). From this initial formalization of trauma-based
disorder, beginning a slow opening of psychological purview over trauma. The DSM-IV
pivotally instituted a more distant standard for trauma. The confrontation with a trauma could
warrant a PTSD diagnosis under the DSM-IV, rather than a direct encounter with anything
life-threatening or awful (APA, 1994; McNally, 2003). The psychological community began
seeing a wider range of trauma victims; whether this change was a removal of blinders or a
decline of prescription is still up for debate. The PTSD diagnosis began to incorporate the
experiences of the general population more and more; Horwitz and McNally both note that the
line between normative distress and disordered distress became blurred (Horwitz, 2018;
McNally, 2003).
At this time, an important signifier of cultural and clinical complication began to spread.
McNally and Horwitz both touch on the Recovered Memory Movement and the capacity it had
to enrapture patient and practitioner alike. This movement was hinged on the concept that
traumatic memories could be repressed to the point that only therapeutic intervention could
resurface the trauma; this theory became particularly attendant to childhood sexual abuse.
Horwitz implants a disproportionately large portion of writing to this topic - an entire chapter given its somewhat meager timeline in relation to other events discussed, seemingly since it
coalesces with his overarching argument that culture has had too meaningful an impact on the
clinical understanding of PTSD. Nonetheless, McNally still points out the importance of
addressing the public misconstrual of clear research. With the help of some researchers, namely
those who misinterpreted clear findings - such as claiming that children who were struck by
lightning had no recollection of the event due psychogenic amnesia and repression rather than
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organic amnesia from a lightning bolt - traumatic memories became ripe for implantation and
proliferation without the need for an initial trauma (McNally, 2003). In practice, talk of satanic
cults and mass childhood sexual abuse became commonplace, yet more often than not, the talk
could not be substantiated by empirical evidence or verified by other sources; regardless of
whether there was validity in the claims, the poor foundation of the movement undercut any true
offense within it. Yet, with events like that still present in the cultural understanding of PTSD, the
diagnosis struggles to find solid ground in the public eye.
As the diagnosis exists now in the DSM-5, PTSD is still ever-changing. The differential
experience and presentation of PTSD puzzles much of the psychological community still. What
seems ultimately necessary for both McNally and Horwitz is the separation of science and
politics (Horwitz, 2018; McNally, 2003). An important caveat, not presented by those two
authors but rather the author of this paper, is necessary for this plea to exist outside of just
written ideology. Science will always and should always be political to some degree; if there is
no information being drawn from the political, research in psychology can rarely be explanatory,
but instead only exploratory. The plight of McNally and Horwitz derides politics and how it
touches science: either directly - through policy - or indirectly - through public opinion. Ensuring
that science exists in a semi-permeable membrane floating in a pool of politics is the most
grounded and attainable goal. Scientists, particularly psychologists, should have an interest in
doing science for people, in line with their concerns and curiosities. Yet above all else, out of the
same fears that McNally and Horwitz expressed, scientists must prevent politics from violating
empiricism; without the scientific method, science is no different from politics and the synthetic
posturing that comes with them. Misrepresentation of science must be condemned and bad
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science must be appropriately labeled. One might be tempted to remove the human background
from the study of trauma and its effects on people, but we must be able to rely on empiricism
within political rhetoric and social morays. Otherwise, empiricism itself is flawed. The work of
scientists cannot and will not exist in a vacuum.
The Terms and Conditions of Post-Traumatic Stress Disorder
Despite the contentious history over the PTSD diagnosis, there is a strong foundation of
science that has corroborated its existence since the 1980s. Although there is still a lot more to
learn about the disorder, there is much that has been uncovered already. The work that is being
done today is structured on decades of rigorous, peer-reviewed research: research that has
attempted, and widely succeeded, at parsing through some of the complex intricacies of PTSD.
Psychological Models
To better understand PTSD in its great complexity, it must be viewed from a variety of
differing perspectives. Those perspectives manifest, with varying degrees of coalescence, in
different models of the disorder. These models not only help to describe PTSD as a neurological
or psychosomatic phenomenon, but they also inform treatment interventions. PTSD, represented
under several different models, is delineated by Matthew J. Friedman (2021) in the Third Edition
of the Handbook of PTSD: Science and Practice. All models are founded on certain pre-existing
psychological theories, which are, in this circumstance, then used to infer the root of disorder.
Two foundational concepts to some of the PTSD models, and many psychological models
generally, are classical and operant conditioning. The former, Pavlov’s brain-child is best shown
with a bell, a dog, and some meat: a bell rung alone elicits no response in the dog. The meat
alone triggers the dog’s salivation. When the bell is rung when meat is presented to the dog, the
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dog associates the bell’s ring with the meat, and the dog will eventually salivate with just the
ringing of the bell. The latter, operant conditioning, is an interaction between behavior and
environment, environment and behavior. In simplest terms, if a certain behavior results in a
reward, that behavior increases, whereas the opposite is true for behavior that begets a
punishment; the rewards and punishments can oscillate between positive - where something is
added, like a cookie or a shock - and negative - where something is removed, like burdensome
weight or a delightful shiny thing (Akpan, 2020).
These two concepts are the twin girders of the PTSD behavioral model. Mowrer (1960)
developed a two-factor theory, fusing both modes of conditioning, stating that the avoidance of a
fear stimulus is reinforced when that avoidance reduces anxiety experienced from the stimulus;
this attempted to explain the general trend of avoidance following a fear-inducing experience.
Although this model is imperfect, in that reduced fear does not necessarily predict reduced
avoidance, it does underwrite much of the therapeutic interventions we presently employ for
PTSD treatment. The fear-conditioning model follows a similar logic, but more directly applies
conditioning to the reexperiencing-trauma and fear-response dynamic: when an individual is
exposed to a trauma - the unconditioned stimulus - it elicits an unconditioned fear response;
subsequent reminders of the trauma - the conditioned stimuli - then trigger the conditioned fear
response, even if those stimuli are benign in nature, such as a popping balloon reminding an
individual of a gunshot (Friedman et al., 2021). This model does well to explain the hormonal
aspect of PTSD, in which hormones associated with fear response (epinephrine, norepinephrine,
and cortisol) are at abnormal levels (heightened epinephrine and norepinephrine levels; lowered
cortisol levels) in individuals with PTSD for a prolonged period following a trauma, suggesting
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that the fear response is incessantly retriggered by conditioned stimuli (Kosten et al., 1987). The
fear-conditioning model, similar to the behavioral model, illustrates well the nagging impacts a
trauma can have well after the incidence of the trauma. Additionally, both models have provided
the foundation for current treatment interventions like exposure therapy or Cognitive-Behavioral
Therapy with a Trauma Focus (CBT-TF).
Other models of PTSD rely less heavily on conditioning in their explanations. The
information-processing model, rather than focusing on the associations connected with a
traumatic event, touches on the mental processes, like memory and attention, that could be
implicated in the event’s initial interpretation and an individual’s resultant response. It is
suggested that traumatic experiences - those that overwhelm one’s preconceived notions of stress
and fear - are encoded into memory alongside information about what is or could be a future
source of trauma and the responses that should be triggered in preparation for that (Foa et al.,
1989). As a result, individuals develop a fear structure wherein threatening stimuli are more
readily expected and an attentional bias towards threat is formed. In a color-naming,
threat-related Stroop task, participants were presented with either threat-associated words (i.e.
“mutilated”) or neutral words (i.e. “cherry”), and were told to respond as quickly as possible,
ignoring the content of the word, and only stating the color of the word; slower responses to
threat-associated words among the PTSD group were suggested to be indicative of greater threat
interference at a preattentive stage (Harvey et al., 1996; McNally et al., 1990). The treatment in
the information-processing model does not diverge far from those which grew out of
conditioning-based models; it supports the use of progressive exposure and re-rationalization of
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the traumatic event to reintegrate it into normal memory and thereby reduce hypersensitivity to
threat (Friedman et al., 2021).
The dissociative, cognitive, and social models are distinct in a very illustrative way. The
dissociative model hinges on the experience during trauma: whether dissociation occurred, and
how that could inform if or how PTSD manifested. The cognitive model leaps over the trauma
itself and focuses more on the individual’s internal, adaptive tendencies following trauma and
how self-referential cognition could predict PTSD symptoms. The social model looks beyond the
trauma and, uniquely, even the epistemic; instead, it highlights how the external environment
following a threat of trauma could dictate the development of PTSD (Friedman et al., 2021).
The dissociative model puts forth that dissociation during a trauma predicts the
development of PTSD, as supported by evidence that indicates a direct relationship between
peritraumatic dissociation and PTSD, or an indirect relationship through an unknown third
variable as supported by a study that measured the degree of peritraumatic dissociation soon
following a massive explosion in the Netherlands with a high number of casualties; affected
individuals were measured for PTSD severity, intrusions, and avoidance reactions. The study
found significant positive associations at 18 months after the disaster between peritraumatic
dissociation and intrusions as well as avoidance reactions. This suggests a capacity for
dissociation during a trauma to dictate, either directly or indirectly through a mediator, the
manner and timeline of PTSD (Velden et al., 2006). In contrast, other research critiques that
peritraumatic dissociation data and any conclusions drawn from them are based on retrospective
reports, which can be highly unreliable since it is difficult to recall past emotional states;
therefore, it is possible that the association between peritraumatic dissociation and PTSD is
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better attributable to the measures used than a causal relationship (Candel & Merckelbach, 2004;
Marshall & Schell, 2002).
The second model - cognitive - homes in on an important and often understated aspect of
PTSD: an unhealthy initial appraisal of the trauma and the negative reassessments of the incident
that recur upon memory retrieval or trauma retrigger. The cognitive model understands PTSD in
a very present sense. The continuous damage of negative self-appraisal and unstoppable intrusive
memories is the problem of PTSD, not necessarily of the trauma. Ehlers and Clark (2000)
postulate a cognitive model of PTSD persistence in which, not only the constant negative
appraisal of the trauma perpetuates PTSD symptoms, but a memory of the traumatic event being
miscategorized and poorly integrated into autobiographical memory - without a sense of context
or information surrounding the event results in intrusive memories and subsequent hyperarousal
and hypervigilance. These specific symptoms of PTSD likely manifest due to the fact that
traumatic memories that are poorly integrated and elaborated in autobiographical memory are
much more often retrieved through automatic processes (i.e. response to a triggering stimulus)
rather than controlled processes (i.e. intent to recollect a memory). The cognitive model, as
described above, leads directly into particular forms of treatment, such as Cognitive Processing
Therapy (CPT), in which individuals reassess traumatic memories and work through unhealthy
cognitions and behaviors - also referred to as ‘stuck points’ - around them; with the goal in mind
of integrating and elaborating traumatic memories in autobiographical memory, unhealthy
memory retrieval patterns in PTSD might be curbed (Watkins et al., 2018).
The third in this grouping and final in this whole series of psychological models is the
social: less widely used than the others but no less important. When an individual must bargain
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with a traumatic experience, the social model posits that attachment theory - the concept that
people’s willingness to emotionally connect with another person varies between individuals centers itself in that exchange. In that, the capacity for one to deal with a trauma is strongly
influenced by one’s attachment security and the access to, or amenability to access, social
support. This is best substantiated by a meta-analysis that shows seeking attachment or social
support following a trauma can improve PTSD outcomes, and the lack of social support is one of
the strongest risk factors for PTSD following a trauma (Brewin et al., 2000). As well, it was
found that just pondering a figure of attachment (i.e. “Mom”) helped to regulate levels of
hormones implicated in negative trauma-based alterations after participants were subjected to
physiological arousal (Bryant & Chan, 2015). The broad and valuable takeaway from this model
is that attachment styles could inform the development of PTSD and robust social support should
always be the standard for non-directive, or even non-clinical, treatment.
An important note that Friedman et al. (2021) make about these models, which this paper
endorses as well, is that they each exist independent of one another, but function best when
viewed as part of a whole. Stress-related hormones, such as the norepinephrine and
glucocorticoid systems, manage the mind and body’s most immediate response to a stressor. The
potential dysregulation of those hormones can result in chronic stress or hypervigilance.
Hormone activation simultaneously creates an association between fear and stress-related stimuli
which can be subsequently activated well after the trauma has occurred. All information and
memories surrounding the event are prejudicially encoded, resulting in an attentional bias geared
towards threat, fracturing the event into sensory-based stimuli. Fragmentation of the memory
places it outside of the autobiographical memory system, preventing it from being appropriately
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reprocessed and overcome. Appraisal processes influence how the intrusive memories of a
traumatic event are reconceptualized, for better or for worse, and, tangentially, social interaction
guides the acceptance of a trauma and the track of PTSD symptoms, for better or for worse.
These individual factors - aspects of different models - interact more extensively than
their individual definitions suggest, but the generality of this explanation illustrates how PTSD
can best be viewed from an array of perspectives at once. PTSD is multifold; it might appear to
be complicated by an intertwining of different explanatory models, yet a broad view of the
disorder is still necessary until research has grasped its full span and specificity. Since the current
treatment out in the clinical world has been shaped by these models, the models themselves can
provide an insight on how to generate novel treatment that works off of the successes and failures
of the current standard. The different ways in which PTSD is conceptualized provide a mapping
of potential treatment avenues; it seems as if constructing PTSD from a variety of perspectives is
the most accurate and appropriate approach, so treatment might function similarly. A treatment
that holistically addresses PTSD’s varied symptoms could be the most accurate and appropriate
approach; to that point, psilocybin-assisted therapy shows holistic potential.
Serotonin in PTSD
Moving from the general to the specific, from models to minds, neurology takes over. To
start a deep dive into functional neurology, a good starting place is with the key components to
brain communication: neurotransmitters. They are messengers and messages of the brain, and
they play a part in both normal and abnormal functioning. Of course, this implies that certain
neurotransmitters have their own piece of the culpability pie in PTSD. The brain shocked by a
traumatic experience undergoes extraordinary anxiety and stress. This demands extra resources
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from certain neurotransmitters. This is particularly vital when considering the neurotransmitter,
serotonin, since one of its primary roles is as intermediary for behavioral inhibition. Having an
active serotonin system, particularly in the 5-HT section, can result in stress resilience and
prevention of trauma recurrence (Connor & Davidson, 1998; Frazer & Hensler, 1999). By the
same logic, a hindered serotonin system is a risk factor for the development and persistence of
PTSD. This warrants the use of selective serotonin reuptake inhibitors (SSRIs) for PTSD, which
specifically target the 5-HT system to enhance resilience to stressful stimuli and recurrent
traumatic memories (Corchs et al., 2009). For the sake of both prevention and treatment,
serotonin is an incredibly important factor.
Neuroplasticity
Just as with its capacity to communicate, the brain’s capacity to change should not be
undervalued. The human ability to adapt to new environments, challenges, and, notably, stressors
is what has propelled us into our own realm outside of the natural world. In contemporary
society, one’s capacity, not necessarily to change one’s mind, but for one’s mind to change,
distinguishes adaptive from maladaptive behavior. This trend carries over to environments of
stress and trauma; if the brain is able to accommodate outlying experiences into proportionate
behavioral responses, it is to the benefit of the individual. And yet, if that response persists after
the stressful or traumatic stimulus has already gone - the brain molds its form around chronic
stress - it can be particularly harmful to the individual, as seen in PTSD.
The phenomenon responsible for this adaptability that human brains share is something
called synaptic plasticity or neuroplasticity. These terms refer to the brain’s faculty to form new
connections between neurons or alter existing ones by forming new or removing old synapses -
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the liminal space between neurons through which neurotransmitters are passed (Abdallah et al.,
2017). Taking this into the context of PTSD, trauma is a particularly trying test of synaptic
plasticity. The ability to integrate a stressful experience into existing memory and self-referential
cognitive mechanisms can help to ward off PTSD, but it might necessitate a capacity for
adaptation (Foa et al., 1989).
As already referenced in the information-processing and cognitive models, individuals
with PTSD experience a failure in fear processing and memory consolidation. Vital to
understanding PTSD in relation to synaptic plasticity, PTSD could be explainable by an
impairment to synaptic plasticity that inhibits an updating of those processes essential for
negotiating trauma, like fear extinction (see Figure 2, Mahan & Ressler, 2012). That impairment
shows itself in vital brain regions like the hippocampus, amygdala, and prefrontal cortex, which
are most significantly implicated in memory processing, emotional processing, and emotional
regulation. Failures in something like fear extinction might be partly explained by a gene
mutation. In a study of 72 participants, half with a specific gene mutation (Val66Met) in the
brain-derived neurotrophic factor (BDNF), which is
thought to be the main propulsion for brain cell growth
and function, participants were presented with an
aversive stimulus that was paired with a neutral cue.
After pairing, the then-conditioned cue was presented
without the aversive stimulus. Participants with the
gene mutation were slower to lose the conditioned fear
response, indicated by skin conductance, than the
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non-gene mutation participants, suggesting impaired extinction in the gene mutation group
(Soliman et al., 2010). The presence of this individual genetic difference is correlated with
altered activation in the hippocampus, amygdala, and prefrontal cortex, hinting at a meaningful
relationship between the brain-derived neurotrophic factor gene and synaptic plasticity in these
regions (Mahan & Ressler, 2012).
Another possible root of failed synaptic plasticity is chronic stress’ effect on long-term
potentiation (LTP) in the hippocampus. Long-term potentiation is the mechanism, theorized to be
behind learning and memory, which involves the strengthening of neural connections after
repeated use. In a study conducted on 27 rats, half were restrained and tail-shocked 30 times over
the span of 30 minutes while the other half were unrestrained and not shocked for 30 minutes.
Evaluating a specific layer of the rodent hippocampus, long-term potentiation was significantly
impaired in the shock group when compared with the non-shock group (Foy et al., 1987). This
suggests that the stress, and helplessness to remediate that stress, inhibited synaptic plasticity in
the hippocampus (Kim et al., 2015). These are just two potential explanations for failures in
synaptic plasticity that might precede PTSD, but there are many more possibilities. Despite any
uncertainty in its causes, it is known that failures in synaptic plasticity are problematic for the
mind and the body; without the capability to alter modes of cognition, trauma sticks in the
memory, radicalizes the emotions, and forces mental stagnancy.
Triple-Network Dysregulation
Select brain regions have differential relationships with different disorders. Alterations in
certain regions are pivotal for the present conceptualization of how disorder manifests. With
PTSD specifically, a large network of brain regions is appearing more and more vital to the
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disorder and its treatment. Due to recent advances in neuroimaging, it is possible to evaluate
brain region connectivity more holistically, parsing through noise better, targeting analysis with
greater spatial specificity, and, importantly, detecting resting state data - data gleaned from
functional magnetic resonance imaging (fMRI) when an individual was not performing a task
(Goulden et al., 2014). These new capabilities ushered in data on three relevant networks that
compose a greater network among themselves. This triple-network is made up of the Central
Executive Network (CEN), the Default Mode Network (DMN), and the Salience Network (SN).
The most broad relationship that has been ascertained about this network and its constituent
components is that the Central Executive Network is involved in cognitively demanding tasks
while the Default Mode Network is activated most in a resting cognitive state - in ponderance and the two take part in a zero sum game of cognitive resources. Since the two are activated with
mutually exclusive processes, activation tends to be nearly completely distributed to either one
network or the other (Sridharan et al., 2008). To date, it’s postulated that the Central Executive
Network is comprised of dorsolateral prefrontal cortex (dlPFC) and posterior parietal cortex and
the Default Mode Network is made up of posterior cingulate cortex (PCC), posterior parietal
cortex (PPC) and the ventromedial prefrontal cortex (vmPFC). The Salience Network primarily
serves the purpose of responding to stimulus or sensation that appears important; in the
triple-network, it is responsible for modulating the commutative relationship between the Central
Executive Network and the Default Mode Network. The Salience Network is made up of
ventrolateral prefrontal cortex (vlPFC), anterior insula, and the anterior cingulate cortex (ACC)
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(Goulden et al., 2014; Porto et al., 2018; Wang et al., 2019). With this rag-tag trio forming a
chaperoned push and pull, the question arises: can the group fall out of balance? Also, what
happens if they do?
Well, looking at this through a lens of trauma, imbalance of the triple-network is not only
possible, but very likely. With imbalance comes serious implications for cognitive and behavioral
functioning in the form of PTSD symptomatology. There is a wealth of information regarding
PTSD that can be drawn from this broad network, yet only some of the most pertinent to
symptom manifestation is presented here. In a sample of 20 survivors of a coal mining flood
disaster, divided by PTSD diagnosis, connectivity within different regions of the three respective
networks were all significantly decreased in the PTSD group when compared with the healthy
group (Liu et al., 2017). In the Central Executive Network, the significantly decreased
connectivity was chiefly in the left middle frontal gyrus. This is noteworthy given a study on
participants with sexual assault trauma exposure, half with PTSD and half without. In that study,
it was found that connectivity in the left middle frontal gyrus on fMRI was significantly
decreased in the PTSD group when presented with negative affective pictures compared to the
non-PTSD group (New et al., 2009). This suggests that within-network disconnectivity in the
Central Executive Network - a hub of higher-level processing and top-down control - may be
responsible for emotional dysregulation in PTSD. Additionally, it was found that this
disconnectivity in the Central Executive Network was significantly correlated with greater PTSD
symptom severity, reinforcing the argument that this network is related to emotional failures
specific to PTSD (Liu et al., 2017).
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Given the Default Mode Network’s role in self-concept, the greater within-network
disconnectivity under PTSD could be influential on the sense of self. Two pivotal components to
the network, the medial prefrontal cortex (mPFC) and lateral orbitofrontal cortex (lOFC), showed
decreased between-region connectivity significantly correlated with greater PTSD symptom
severity (Akiki et al., 2018). Along with that, the medial prefrontal cortex was found to be
particularly important for self-referential processing in a study with 30 healthy participants; the
grouping of participants who were asked to recall self-referential descriptor words displayed
better recall and higher activation of the medial prefrontal cortex on fMRI when compared to the
grouping who were asked to recall descriptor words about an intimate other (Heatherton et al.,
2006). Thus, the medial prefrontal cortex both plays a necessary role in self-concept and shows
greater disconnectivity with PTSD. It wouldn’t be inconceivable that these two factors result in
PTSD’s negative alterations in self-concept like depersonalization and dissociation from self.
Aligning with the function of the Salience Network, to detect salient phenomena, the
dysfunction of the network under PTSD appears to alter that necessary and constant process. In
45 participants, split by PTSD participants, combat-exposed healthy participants, and
non-combat-exposed healthy participants, greater connectivity was found within the Salience
Network, particularly the insula, on resting-state fMRI in the PTSD group when compared with
controls. In that same study, higher connectivity with the right anterior insula was correlated with
higher PTSD severity scores, particularly hyperarousal symptoms (Sripada et al., 2012). Given
the role that the insula, and Salience Network generally, plays in the assessment of stimuli,
heightened activation could speak to a lower threshold in recognizing salience, or alternatively
described as hypervigilance (Friedman et al., 2021). The Salience Network plays a fundamental
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role in the regulation of the two other networks; therefore any dysregulation in one likely speaks
to a dysregulation in the other two (Friedman et al., 2021; Liu et al., 2017).
The whole span of intricate network changes under PTSD cannot be delineated here, but,
in total, it appears that the dysfunction of these three networks and their pivotal, ingredient
regions, whether through increased or decreased connectivity between different components, is
tied in with PTSD’s manifestation and how different aspects of symptomatology present.
Although it appears ever-more likely that this large network is responsible for much of PTSD’s
symptomatology, Liu et al. (2017) make the weighty point that the different presentations of the
disorder - slight alterations in symptoms possibly due to different trauma types or genetic factors
- may eventually be mapped onto different activation patterns in this network. The triple-network
plays a role in memory, emotion, perception, and nearly every aspect of cognition, so it is not
unrealistic to attribute much of PTSD as it is currently understood to traumatic changes in this
complex network.
Network Segregation and Integration
The brain is unremittingly taking in an influx of information, sensed from a near-infinite
source of stimuli. Such a vast intake requires an organization into which the information is
filtered and manipulated. This compartmentalization is a natural, necessary process for the
functioning of the human organism. The dynamics of connection and separation form the
topography of the brain and inform the relationships throughout it. Integration is the yardstick for
measuring how well a brain region receives different information and processes it within a
network. Segregation is understood as a complementary function to integration in which
information is designated to only individual regions within a network in order to efficiently
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organize and process different information (Lord et al., 2017); segregation can be alternatively
understood as a metric for the localization of brain function to a given network.
A good example of these processes is a study of 35 young and healthy participants. They
were presented with two separate tasks - one, a simple, motor skill task, and the other, a
cognitively-demanding memory task - and were evaluated with global-brain fMRI. In the simple
task, participants showed significantly higher segregation, with more within-network activation.
Conversely, the participants in the demanding task showed higher integration, with more global,
between-network activation. Since the simple task required only specific activation of motor-skill
related regions, greater segregation was efficient. Since the demanding task required a variety of
different brain regions, greater integration was adaptive. In healthy individuals, integration and
segregation develop a harmonious balance based upon cognitive demand (Cohen & D’Esposito,
2016). Naturally, the network changes elicited by integration and segregation are intrinsically
linked with synaptic plasticity. Although the integration and segregation are mostly focused on
large-scale network change, that reconfiguration is also happening on a small-scale at the
synaptic level (Cohen & D’Esposito, 2016; Lord et al., 2017). Yet, in the context of disorder, the
conversation around dysregulated integration and segregation focuses more on how the brain has
changed rather than whether it still has the capacity to do so.
In different neuropsychiatric disorders, integration and segregation present differently. In
individuals with Major Depressive Disorder (MDD) and Bipolar Disorder (BD), fMRI has found
reduced segregation and integration in specific portions of the Default Mode Network. This
suggests a failure of localized function and variable information intake during emotional
processing and self-referential processing. Also, in individuals with Major Depressive Disorder
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there was greater dynamic segregation in the putamen - a brain region, not part of the Default
Mode Network, but still important for its role in mood and motivation - which could inform the
impenetrable negative cognitions of the depressive disorder (Luo et al., 2021). Looking over to
individuals with schizophrenia, lower segregation has been observed in the primary sensory and
motor cortices as well as the thalamus when compared to individuals of high-risk to
schizophrenia but without the diagnosis. The decrease of short-range connections within these
regions necessary for sensory intake and top-down function, could explain schizophrenic
symptoms like paranoia and hallucination. As well, individuals with schizophrenia also displayed
higher functional integration in the prefrontal cortex; over-integration in a region already so
important for coalescing varied sensory input could result in abnormal or muddled output (Duan
et al., 2019).
Integration and segregation have also shown to present uniquely in PTSD. Segregation
has shown to be hindered particularly in the prefrontal cortex. This suggests that the prefrontal
cortex is limited in performing its specialized functions, one of which is exerting top-down
regulation on other brain regions. This specific hindrance is important because it has more
general implications beyond one cortex; if the prefrontal cortex is showing lowered segregation,
it could mean a variety of brain regions, like the amygdala and hippocampus, are poorly
optimized for their specific functions. The capacity to ward off unconscious intrusion is a
function that would be thereby hindered (Spielberg et al., 2015). Adding to the dysregulation, it’s
been observed that the segregation in the occipital and subcortical networks increase; this
increase provides the other half of the story, in which, without the top-down prefrontal control,
regions important for emotion, memory, and attention become highly internally active
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(Rangaprakash et al., 2019). As for integration, the impact is rather similar in these regions.
Subcortical-, parietal-, and occipital-associated nodes (outside of the prefrontal region) all
showed higher integration in PTSD than control, hinting at a generally overactive or inflated
regions of the brain without the necessary control functions. However, in total, on a global brain
scale,

integration

segregation
PTSD

was

than

and

lower

control.

in
This

seems to mean that specialized
processing fails and effective
communication

is

limited

under disorder (Rangaprakash
et al., 2019). This neurological
profile suggests that PTSD
creates a disorderly, inefficient brain.
Depression Comorbidity
Discouragingly, comorbidity is a rule rather than an exception in PTSD. To overlook it in
concept or treatment is to ignore most of the disorder and to ignore many of those afflicted. With
30-50% of individuals with PTSD also meeting criteria for a depression diagnosis, or Major
Depressive Disorder (MDD), considering depression symptoms alongside those of PTSD should
be a standard (Angelakis & Nixon, 2015). Such a high rate of coincidence truly muddles the
view of PTSD as independent. In conceptualizing PTSD, one must be able to separate the distinct
neuro-cognitive phenomena and resultant symptomatology of PTSD and depression. In
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remedying the disorder, one must create a standard of treatment, but that could be by addressing
PTSD alone or establishing comorbid-specific interventions. The question stands tall in the
psychological community: how can we understand PTSD and depression together, and moreover
how can we treat it?
The roots between the two disorders are so deeply intermeshed that the diagnosis of
comorbid depression and PTSD is not entirely distinct from PTSD alone. In fact, it is even
suggested that, following a trauma, co-occurring depression and PTSD should not be viewed as
separate constructs but a singular traumatic reaction (O’Donnell et al., 2004; Post et al., 2011).
The implications that this carries for the diagnosis of psychological disorder is significant. If the
only unique aspect of diagnostic criteria is the initial cause (i.e. a traumatic event), the diagnosis
has the capacity to do more harm than good by drawing arbitrary distinctions where,
meaningfully, there are none. However, the most optimal approach, in the present understanding,
is to conceptualize PTSD and its comorbidities as distinct diagnoses that have overlapping
presentations (Barbano et al., 2019; Post et al., 2011).
The two disorders, even when considered distinct, destructively work in tandem.
Depression heightens the risk of developing PTSD and PTSD is also a risk factor for depression
onset following a trauma (Angelakis & Nixon, 2015). PTSD alone poses high risks for
suicidality, but even higher in individuals with comorbid depression (Nichter et al., 2019;
Panagioti et al., 2012). To boot, quality of life, emotional well-being, and broadscale mental
health are at their worst between PTSD and depression than at either of the poles (Nichter et al.,
2019). They simultaneously manifest at such a high rate and pose such severe detriments in their
overlap that an overwhelmingly distressing situation is created for anyone caught in the middle.
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Therefore, treatment is of extremely high import. Yet still, treatment too is complicated
by comorbidity; depression has the potential to diminish treatment outcomes for interventions
specifically targeting PTSD (Angelakis & Nixon, 2015). With that, it is necessary for treatment
to consider the overlap. Even if PTSD and depression are truly distinct, the imbrication between
the two co-occurring disorders is vast enough that comorbid-specific treatment should not just be
an exception. Novel treatment interventions are being actively employed to address PTSD and
MDD’s comorbidity. One of these is Behavioral Activation Therapy (BA), which has shown
success in addressing the dual complexity, improving participant quality of life and depression
alongside the reduction in PTSD symptoms (Jakupcak et al., 2010; Mulick & Naugle, 2004).
Following this guideline of more comprehensive intervention, treatment outcomes will hopefully
improve for a broader population. Treatment for PTSD unfortunately cannot be limited to the
diagnostic criteria of just PTSD; the complexity of this far-reaching disorder must beget a
clinical response of proportional holism.
First-line Treatment
In crafting the appropriate clinical response to a disorder, understanding the models of the
disorder and its neurological idiosyncrasies may help guide part of the way, but exploring the
active treatment methods can help with the rest. In the present day, the primary interventions for
PTSD are psychotherapy. Cognitive Behavioral Therapy with a Trauma Focus (CBT-TF),
Prolonged Exposure (PE) therapy, and Cognitive Processing Therapy (CPT). As the name would
suggest, Cognitive Behavioral Therapy, usually around 10 sessions, incorporates both cognitive
and behavioral techniques, such as cognitive restructuring and exposure respectively. In the
traumatic context, the former focuses on replacing unhealthy beliefs or thoughts about the trauma
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and self with rational thought. The latter focuses on imaginal exposure to the trauma and
employing different techniques of recollection (Watkins et al., 2018). These individual
components contribute to a moderately successful treatment with relatively low chance for
relapse (Bryant et al., 2008). Prolonged Exposure therapy, which usually spans about 12
sessions, is rather self-explanatory as well; the goal is to repeatedly expose patients to their
trauma over and between the session periods in order to better integrate the experience into
existing emotional and rational thinking; this approach, with adaptable methods, appears to be
effective for a wide variety of patients (Rauch et al., 2012). Lastly, Cognitive Processing Therapy
targets illogical thinking that can contribute to negative self-value and hypervigilance. A large
part of this process is the addressing of “stuck points”: a patient’s persistent and problematic
misconceptions regarding the traumatic event. When not properly addressed, these “stuck points”
can result in self-loathing and self-blaming, worsening the impact of PTSD and preventing new,
ameliorative thoughts on the incident (Resick et al., 2016). Cognitive Processing Therapy has
been successfully implemented into treatment for a wide variety of trauma types (Watkins et al.,
2018).
And yet, despite the success that these different interventions have had, there is an
overwhelming downside to them, a common thread: the exposure basis. Whether it’s imaginal,
written, or vocalized, reexposure to trauma can be incredibly difficult for even the toughest
patient. This arduous aspect of PTSD therapy results in a large minority dropout rate (Hembree
et al., 2003). It also means that certain high-risk populations (i.e. high suicidal ideation rate) are
often not provided with these first-line treatments. Given a high attrition rate, one might look
beyond psychotherapy. Yet, pharmacological intervention does not provide much of an
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alternative or supplement to therapy; the selective serotonin-reuptake inhibitors (SSRI) approved
for PTSD are not broadly applicable to disorder treatment (DePierro et al., 2019). More work is
needed to apply treatment effectively to more people within the PTSD complex. More
specifically, given that exposure therapy, when it is withstood, seems to effectively address
PTSD, treatment to supplement that therapy and render it more palatable could be the appropriate
next step.
Combat Trauma
When considering novel treatment for PTSD, there are a slew of factors that cannot be
overlooked. The mechanisms mentioned above illustrate some of the underlying factors that both
explain and complicate the current modes of treatment intervention. There are numerous pieces
to the treatment puzzle and some are not exclusively reserved to the brain. Taking a step away
from the neural domain allows a broader view of PTSD in its different shapes and colors. Outside
of the brain and the individual exists a pivotal origin: the trauma. The specifics of the event that
precipitated the disorder manifesting are incredibly important for understanding the specifics of
the disorder. This paper, for several reasons, is concerned with a specific type of trauma: combat
exposure. For starters, combat-related trauma, on average, shows the highest symptom severity
out of all trauma types, significantly greater than all but sexual trauma (Guina et al., 2018). In the
realm of treatment, military populations with PTSD show worse outcomes than civilian
populations (Straud et al., 2019). So, part of the rationale for focusing on combat-related trauma
is necessity; in this study it might be possible to determine whether the proposed novel treatment
is effective with even the most treatment-resistant population.
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The other side to this rationale is rather political in nature. Veterans are a unique
population in the American sociopolitical sphere; they garner bipartisan support in a way that
most disenfranchised populations do not. Adjacent to their political position, is the large
roadblock to the political progress of psychedelics: leftover, right-wing stigma from the
psychedelic movement in the 1960s (to be expanded upon in the next section) and Reagan’s War
on Drugs in the 1980s is still endorsed by many, veterans included. Yet some veterans have
managed to see past it, often out of a necessity for treatment. If psychedelic treatment continues
on its successful course, it is likely that the treatment will eventually become accessible to more
people, including veterans. The narrative of psychedelics can be significantly shaped by the
veteran population, for or against it; practically, veterans are a necessary ally in the political fight
for psychedelic acceptance. Ensuring that the treatment works effectively and safely with
veterans both follows good research practice and sociopolitical practice. Above all else, even
without their function as a political tool, this treatment is owed to the veterans. Out of the other
PTSD populations, veterans with combat-related trauma are a group that the government is most
directly responsible for helping. By waging wars and offering a flawed healthcare system to its
soldiers upon their return, the government has tacitly failed one of its most ‘treasured’
populations. Now the government, with scientific substantiation, has the capacity to help those
who have suffered its transgressions by rescheduling pro-therapeutic psychedelics. Withholding
that federal action would be perpetuating further harm. If the government truly cares for its
veterans and the suffering they’ve endured, it will follow the science and support this research
however possible. This study, therefore, wishes to reinforce that call for long-owed treatment to a
population of great concern.
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Shrooms, Tycoons, and the Boons of Their Research: A History of Psilocybin Mushrooms
in the United States
Fungi persists. It has existed since before human animals, has been the life and death of a
myriad Earth’s evolving creatures, and has abided apocalypse, unwavering (Schwartzberg, 2019).
Dating back to prehistoric times, psychoactive off-shoots of fungi were present and consumed by
humans. From then, indigenous groups, most notably the Mayan and Aztec cultures, revered
mushrooms and assimilated the psychoactive kinds into religious and medicinal practice
(Winings, 2021). Psychedelics cannot and should not be integrated into Western standards of
clinical practice without first recognizing its roots in indigenous tradition with and reverence for
the mushroom; a culturally-informed approach to psychedelic treatment is the only approach that
respects its own foundations and forebearers.
This paper is focused on the most current Western practices of psychedelic treatment,
therefore the history of psilocybin that is rendered in this paper is focused on the psychedelic
tumult in the United States and how that led to the research practices of today. This history is
heavily influenced by the work of Michael Pollan (2018), specifically his book How to Change
Your Mind, in which he speaks on his own uncovering of the rich world of psychedelics and the
research he did with some of the largest proponents of these eclectic substances. Although Pollan
himself is no expert on psychedelics, he constructs his work from experts of different
backgrounds with different opinions; Pollan does a good job to nuance his perspective as an
outsider and, to the reader’s benefit, incorporate conflicting viewpoints. There is no perfect
history of psychedelics in the U.S., but Pollan does well to recount it from an honest standpoint.
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In the early-to-mid Twentieth Century, the Western world was coming to terms with the
trauma of rampant war and discrimination; a group of molecules were working their way over
the borders, bound for popular disruption. In the United States, psychedelics were thrust into the
zeitgeist by researchers sure only of their uniqueness, but relatively ignorant of their ability to
affect unprecedented change on both a personal and cultural level. The term “psychedelic” - what
was once a completely alien collection of syllables - became a colloquialism on par with
“radical” or “cool” for some, and for others, a signifier of anti-patriotism from a misguided
youth. One of the primary vectors for this psychedelic polarization was the banker,
anthropologist, and amateur mycologist R. Gordon Wasson after he recalled his psilocybin
(4-phosphoryloxy-N,N-dimethyltryptamine) experience in Life magazine. In the June of 1955,
Wasson’s trip in Huautla de Jiménez, Oaxaca with the guide, or curandera, María Sabina elicited
a frenzy of interest in the rousing substance - a frenzy which would dictate the newest dichotomy
in American politics for the coming decades and one which would tarnish the small town of
Huautla and fill a once-welcoming María Sabina with regret.
Yet, a very similar molecule managed a more covert introduction into the western world
as, about a decade prior in 1943, Albert Hofmann accidentally synthesized Lysergic Acid
Diethylamide (LSD) when attempting to develop a pharmaceutical for improved circulation; his
first time testing the substance, which happened to be on himself, resulted in a life-changing
surprise as he was sent on a trip well beyond the circulatory system. By 1950, after Hoffman
produced the twenty-fifth molecule in the series, or LSD-25, and word of his personal experience
transcended his Swiss lab, the molecule was being thoroughly examined and tested. For some
time, LSD was believed to induce a form of madness. It was therefore tested for the insight it
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could provide into schizophrenics and psychotically-disordered individuals (this type of
pharmaceutical can also be referred to as a psychomimetic). A concept now commonplace in the
professional and recreational realms of psychedelics is the importance of set and setting pre- and
peri-trip. That is, it is vital to pay particularly close attention to one’s state of mind and all
aspects of the venue in which the trip will take place when planning a trip, as these two variables
can entirely shift a psychedelic experience for better or for worse.Working off of that, given how
impactful a tripper’s hopes and expectations can be on the psychedelic trip, when participants
anticipated madness when taking ‘psychomimetic’ LSD, that is precisely what they experienced;
subjects witnessed horrifying images and underwent a duress so great that it began to resemble
the disordered experience they initially anticipated. Despite the horrors that arose from this
psychotomimetic model, patients treated with LSD surprisingly still found remission from their
habits (Mangini, 1998). As the world of psychology started a slow move away from purely
behaviorist methods of analysis, wherein a subject’s opinion and felt experience was not of
scientific value, the testimony and perception of LSD participants started to hold more weight;
the transcendent and ecstatic aspects of psychedelic trips appeared to be at odds with
psychomimetic conceptualization of psychedelics.
What arose from this conflict were two new models: psycholytic and psychedelic. The
former believed existing psychodynamic processes were just heightened under these substances
while the latter postulated that the experience was an entirely separate form of mysticism or
emergent functioning (Di Leo, 1981). Research under these models moved psychedelics into a
more mainstream treatment structure, addressing addiction, depression, anxiety, and other
disorders (Chi & Gold, 2020). By the start of the 1960s, psilocybin and LSD were both being
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utilized in a great breadth of research. Their results were promising, particularly to those
conducting the research. However, at the end of the decade, psychedelics had not yet ‘escaped
the lab.’ There was a storm of controversy yet to touch ground, but with the help, and more
importantly distribution, of figures like Timothy Leary - Harvard’s champion of psilocybin and
salaciousness - and Al Hubbard - “The Johnny Appleseed of LSD” - psychedelics would bound
from research to recreation. Although lesser-known good research would continue being
conducted throughout the 1960s, the popular narrative around psychedelics would stop reflecting
that (Butler et al., 2020).
Celebrities were swept into the surge in psychedelic fervor, bringing their experiences
under altered states of consciousness into the spotlight, advertising existential relief to the
masses. Al Hubbard, an anomalous man with inexplicable federal and monetary connections,
dedicated himself to ‘liberating’ great swaths of noteworthy figures in the 1950s and 60s with the
help of an inordinate amount of LSD. As 1960 dawned upon the United States, the lugubrious
Harvard professor, Timothy Leary, dedicated himself to a similar path as Hubbard but rather with
psilocybin in hand and a research foundation beneath him. However, unlike Leary, Hubbard’s
personal credentials in research were entirely fraudulent: he toted a false PhD. Despite Hubbard’s
more bizarre beginnings and discordant placement within the world of psychedelics, Leary is
most often labeled as responsible for triggering an enraged opposition to these new substances by
placing himself, his fiery rhetoric, and shoddy research at the heart of psychedelics. Although his
work started more conservative in the early 1960s with a tenuous respect for controls and
blinding, yet none for subject population, Leary’s later work in the Harvard Psilocybin Project
lost any semblance of good experimental practice, bucked for an over-intellectualized cult. As
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Leary, within a greater counterculture, pushed back against the war effort and federal regulation
of any kind, President Nixon denounced Leary and psychedelic-use; most onlookers were forced
to take a side, not only on the average bipartisan politics, but psychedelics as a whole. There was
a certain inevitability for such potent and enrapturing substances to be seized and suppressed
after ‘escaping the laboratory,’ so the blame cannot be left entirely at Leary’s feet, but he
certainly did his part to stoke the flame and endanger the research.
Anti-psychedelic propaganda spread across the nation as fast as the term “psychedelic”
had about a decade before. Some of the indoctrinating rhetoric was founded in reality, like the
role LSD played in the Manson Murders and numerous testimonies of psychosis. Yet most were
unfounded, like, for example, the belief that one’s chromosomes could be disrupted with
psychedelic use. Once Leary was on the lam for marijuana charges in the latter half of the 1960s,
the U.S. government started cracking down on all involvement with psychedelics. As LSD and
psilocybin were labeled illegal substances, nearly all structures for research and recreation were
flattened. At the turn of the decade, these drugs were named Schedule I substances under the
Controlled Substances Act and no psychedelics were being legally studied in the United States
(except for the Maryland Psychiatric Research Center, which ended its research in 1976). The
field of research on psychedelics would be dormant for decades.
Despite the lack of overt work being done with psychedelics towards the end of the 20th
Century, many, if not all, of the researchers from the psychedelic heyday still faithfully supported
the therapeutic potential of these molecules regardless of their recreational potency and the
public framing that entrapped them. With a 2006 study conducted by Roland G. Griffiths at John
Hopkins University, the first rumblings of the eruption that was to be the psychedelic renaissance
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began. This study, the first to receive U.S. Food and Drug Administration (FDA) approval for
psilocybin since the Controlled Substances Act took place, focused on the mystical aspect of
psychedelics and the subjective importance of the altered-state experience (Griffiths et al., 2006).
As this study navigated a thorough evaluation of the research practices and a brief media frenzy
that harkened back to the fervent 1960s, the research field kept moving forward, one measured
step at a time. LSD, psilocybin, ketamine, 3,4-methylenedioxymethamphetamine (MDMA) have
all been tested in randomized controlled trials (RCT) since that Griffiths study. Moreover,
esketamine (a patented off-shoot of ketamine) has been approved for clinical use for depression,
now listed as a schedule III drug. MDMA and psilocybin have been designated by the FDA under
breakthrough therapy statuses for PTSD and depression respectively; they are on the track for
rescheduling. With researchers like Michael Mithoefer and Jennifer Mitchell, like Robin
Carhart-Harris and Roland Griffiths, this psychedelic renaissance is being carried on experienced,
passionate, and dedicated shoulders. As long as the current psychedelic proponents can manage
to eschew the mistakes of the past, the American people may be able to experience more than
just a blinding glimpse of psychedelics.
Shrooman Behavior: The Commerce Between Mycology and Psychology
One starts to wonder, with the fanaticism and demur around psilocybin throughout its
fitful but albeit brief history in the U.S., does it work? How does it work if it really does? Also,
what does it mean for psilocybin to work? All of these questions have now been asked for
decades by layperson and researcher alike, yet the answers are a puzzle yet to be fully solved.
Nonetheless, the knowledge gleaned of psilocybin thus far is promising and awe-inspiring. So,
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please, welcome this psilocybin trip with open arms and an open mind; fear can be a wonderful
thing to lose.
Magic Mushrooms and Their Molecular Mechanisms
Psilocybin ([3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate), alongside
dimethyltryptamine (DMT), is a member of the tryptamine group of classical psychedelics; LSD
and mescaline, other members under the classical psychedelics umbrella, belong to the
lysergamides and the phenethylamines respectively. The distinctions here are just based upon
chemical structure differences between the substances. Psilocybin is also the psychedelic
ingredient in the naturally occurring psilocybe genus of mushroom. However, psilocybin’s effects
alone are not immediately psychotropic: the active ingredient psilocin is the psychoactive
product of psilocybin metabolism; the removal of a phosphate group from psilocybin results in
the formation of psilocin, which readily occurs in the acidic, human stomach . Following that
digestion and prodrug conversion, psilocin enters the intestines and, due to the lipid solubility of
psilocin, it is absorbed and distributed through the bloodstream. Psilocin can then elicit its
psychotropic effects since lipid soluble substances have the capacity to cross the brain barrier
(Bauer, 2019).
It’s worth noting that the process described above is most directly applicable to the
consumption of the mushroom form, but generally in the clinical setting, this is not the preferred
method due to the acrid taste and the meager psilocybin content of a dry mushroom (~5mg of
psilocybin for every 1g of mushroom) (Winings, 2021). Rather, it is more often administered
with a gelatin capsule after development in a lab. The digestion of both psilocybin forms follow a
similar track regardless of their natural or artificial syntheses. However, the artificial synthesis

Gomez, 42

methods of psilocybin are still in their fledgling stages: their yields are not of ideal potency and
are still rather expensive; there is more work being done to find the proper foundations for mass
replication (Lowe et al., 2021). Yet anyhow one chooses to consume the mushroom, its
trademark psychedelic effects occur when it crosses the brain barrier.
So what is a ‘trip’ neurologically? Well the journey starts at the serotonin receptors.
These receptors, previously discussed in relation to PTSD, are protein-based receivers of
chemical messengers, such as the neurotransmitter serotonin; these receptors are implicated in a
slew of neurocognitive processes, like mood, memory, and learning. The majority of serotonin
receptors are found in the digestive tract, but those found in the brain are most relevant to
psilocybin’s psychological effects. Specifically, psilocybin has a high affinity for the 5-HT2A
(5-hydroxytryptamine) receptors, which are largely present in cortical areas like the frontal
cortex (Frazer & Hensler, 1999). This specific subtype of serotonin receptors is a mediator in the
relationship between psilocybin and the rest of the brain. This just means that, if the 5-HT2A
were removed or knocked out, psilocybin would not inspire psychedelic effects in the greater
brain (López-Giménez & González-Maeso, 2017). This relationship coalesces with the main
function of the serotonin neurotransmitter which is to relay messages all across the brain
(Bouchez, 2011). With greater activation of these 5-HT serotonin receptors under psilocybin
versus normal, there is already a greater resiliency to PTSD recurrence, as mentioned earlier
(Corchs et al., 2009). The potency of the psilocybin-affected 5-HT2ARs spans beyond just
serotonin, but it must start there.
Once the digested psilocin binds to the 5-HT2A receptor pathway, it acts as an agonist.
An agonist is a drug that binds to the receptor and causes it to activate, which is opposite to an
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antagonist that inhibits the receptor; drugs that agonistically pair with serotonin, like psilocybin
and other classical psychedelics, are referred to as serotonergics. Psilocin is a particularly potent
serotonergic at the 5-HT2A site, with lower affinities for other serotonin subtypes as well. As
psilocybin is continuously converted to psilocin in the body, the hallucinogenic effects begin and
persist through that pivotal binding site (Bauer, 2019). That agonism appears to precipitate a
wide range of activation and inhibition. In the prefrontal cortex, glutamate, the most prolific
neurotransmitter in the brain, is released after psilocin binding, potentially resulting in the
anxiolytic and antidepressant effects often experienced on magic mushrooms (see Figure 5: Ling
et al., 2022). Most generally, what results following the activation of the 5-HT2A receptor is
broad and varied: a state of consciousness on psychedelics that is referred to as the entropic
brain, highlighting the disorder and irregularity across a wide range of brain regions. Brain
regions undergoing a jolt of fungi suddenly
interact

differently

and

more

globally

(Carhart-Harris et al., 2014). This model of
consciousness provides a foundation for
implementing psilocybin as a remediation to
PTSD neural dysfunction.
Psilocybin and PTSD
Harkening back to the topography of trauma and how it maps onto a brain affected by
PTSD, we can begin to contextualize psilocybin as treatment. In order to cradle a neurocognitive
exploration of psilocybin, the same structure previously used to outline PTSD will be replicated
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anew. Neuroplasticity, the triple-network, and segregation and integration take center stage once
more, hand-in-hand, to expound upon the entropic brain and how chaos might be therapeutic.
An incredibly important aspect to psilocybin, and psychedelics generally, is their
psychoplastogenic capacity, or the ability to induce synaptic plasticity. This, as mentioned earlier,
just means the brain's capacity to develop new connections and therefore alter existing modes of
cognition. Psilocybin is often touted for its ability to ‘change your mind,’ to render the well-worn
neural pathways temporarily disrupted and redirected. In vitro analysis of serotonergic
psychedelics administration on cortical neurons - implicated in the dysfunction of anxiety
disorders - has shown increased dendritic arbor complexity, which just speaks to the aptitude a
neuron has to develop new diverse connections with other neurons (see Figure 6). In vivo
administration of psilocybin has also shown in rats that dendritic spine length increases in the
prefrontal cortex, pointing towards greater synaptic change (Shao et al., 2021). Both structural
and functional plasticity can persist well after the acute effects of classical psychedelics have
diminished (Ly et al., 2018). Looking beneath the cortical structures of the brain, we can look to
the constituent regions of the limbic system. Two of that system’s regions, the hippocampus and
the amygdala, undergo change with psilocybin. Neurogenesis increased for both regions. At low
doses of psilocybin, cued-fear conditioning extinguished faster than control in mice alongside the
alterations in neural connections between, within, and around the hippocampus and amygdala
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(Catlow et al., 2013; Mertens et al., 2020). However it is possible that these brain changes are
not just a result of the drug’s neural mechanisms, but in fact the experience of the drug and its
integration into psychotherapeutic practices cultivates neuroplasticity (Vollenweider & Kometer,
2010).
Therapeutic intervention alongside psychedelics is incredibly important but not
extensively researched; the type and span of therapy has not been drastically varied in the trials
thus far, mainly relying on non-directive approaches. As well, there is still the question of
whether psychedelics should exist in their unfiltered form like magic mushrooms or whether they
should be reduced to a pure ligand to better control the experience and administration of them
(Lowe et al., 2021). However, since the root of this psychedelic-induced neuroplasticity hasn’t
been pinned down, there is no asserting whether the removal of the uncontrolled experience that
is a ‘trip’ would benefit or hinder the therapeutic advantages of the psychedelic. Regardless of
how the neuroplasticity is manifested, there is a link between psychedelics and a rather global
creation of new connections and new neurons, but importantly in areas that are marred by PTSD.
In the world of treatment, getting past the mental stasis that PTSD impels is incredibly valuable,
so psychedelic-assisted therapy might provide a good starting point for that process.
Another way of looking into the psilocybin trip is through the triple-network: the Central
Executive, Default Mode, and Salience Networks. Each of these vital networks go through a
journey of their own once the psilocin molecule reaches that 5-HT2A receptor. Network
alterations as a result of psilocybin are commonly described as changes in circuitry; the crests
and troughs of functional connectivity explain the relationship among the triple-network on
psilocybin. Since much of the research conducted on therapeutic psilocybin administration has
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been directed toward depression, there is a disproportion of writing on the default mode network
above the other two (Ling et al., 2022). Yet, such research is not irrelevant for two reasons;
depression is a large factor in PTSD and if psilocybin alteration of the default mode network
reduced depression symptoms then it could have a similar impact on PTSD symptoms (Krediet et
al., 2020). Deactivation occurs between the posterior cingulate cortex and the medial prefrontal
cortex in the course of psilocybin (see Figure 7). These two regions are large constituents of the
default mode network and are rather
important in self-referential cognition and
appear to be the foundation of the stable
concept of self; it’s been suggested that this
reduction of functional connectivity on
psilocybin can be linked with the egoless
experience often recalled. The deactivation
of these pivotal regions correlates directly
with the subjective effects of the substance
(Carhart-Harris et al., 2012). The default mode network plays an important part in major
depressive disorder, particularly around self-conceptualization. To have reduced activity in this
network could limit the negative cognitions directed inwards that perpetuate depressive cycles,
and could even be productive at curbing unhealthy thought patterns of PTSD, in line with
cognitive models of PTSD and the associated treatment methods (i.e. Cognitive Processing
Therapy).
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Vital to the neurological course of psilocybin are the extensions of the default mode
network; the impacts they have on those brain regions outside of the triple-network also plays a
role in psychedelic remediation. Some regions of the limbic system have a unique relationship
with the default mode network. Under normal functioning the emotion and memory hubs of the
brain - the amygdala and hippocampus - are strongly coupled with the network. On one end,
stronger connection between these regions, under the umbrella of the medial temporal lobe, and
the default mode network has been positively correlated with greater depressive rumination
(Berman et al., 2011). On the other end, psilocybin administration precedes a decoupling of that
functional connectivity, meaningfully separating the default mode network - the self-referential
headquarters - from the amygdala and hippocampus hubs; the stable sense of self starts to draw
away from emotional processing and memory recall. This separation is pivotal for the rationale
of psilocybin-assisted therapy directed toward PTSD; in essence, by removing the ego from
traumatic memories and reducing emotional reactivity, it becomes much easier to come to terms
with those memories and integrate them into normal thinking (Carhart-Harris et al., 2014; Pollan,
2018). The default mode network is so interconnected with the regions involved in disorder, that
sometimes its functioning can perpetuate symptoms. By disturbing the norm of the default mode
network, psychiatric disorder might become less engrained in thought and behavior and therefore
easier to fend off.
To conclude the neural region of this section, the harbingers of neural connection integration and segregation - offer a general explanation for connectivity under the influence of
psilocybin. Using resting-state functional connectivity (RSFC) blood oxygen level dependent
(BOLD) as an indirect indicator of activity shared between regions, it is possible to evaluate how
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regions

maintain segregation and integration in a psychedelic state. Evaluating a

globally-representative sample of resting state brain networks on LSD, it was found that, in
general, these networks displayed less connectivity within their networks and greater
connectivity between networks (Carhart-Harris et al., 2016). This evidence underwrites the
concept of the entropic brain; the reduced internal connectivity speaks to disintegration of brain
networks and the reduced inter-network connectivity speaks to desegregation of brain regions
(Carhart-Harris et al., 2014). This same trend of brain network disintegration and desegregation
carries over to psilocybin as well (eg. Carhart-Harris, 2019; Carhart-Harris et al., 2012; Preller et
al., 2020). Daws et al. (2022) most recently found that global integration increases under
psilocybin, as indicated by fMRI detecting general lowered brain network modularity, or the
measure of within-network connection density. Those brain networks activated through 5-HT
receptors were, by and large, more flexible in connecting outside of their networks. Not only
does the entropic brain seem to explain the experiential facet of psychedelics, but it also could
prove to be a valued remediation to the problematic integration and segregation of PTSD
(Madsen et al., 2021). Interestingly, in PTSD brain measures, those same measures were
reduced. However, it seems as if the chaos of psilocybin is, very importantly, easier directed and
molded than that of PTSD, once again highlighting the importance of structured therapeutic
supplement in and around the acute window of psychedelic effects.
PTSD, when viewed from different angles of disorder, shows a diversity of interconnected
regions dysregulated on local network levels and global connectivity levels. Funnily enough,
psilocybin has a very similar effect, but acutely. The disruption elicited under psychedelic
conditions has the potential to unstick those unhealthy cognitions that have become normalized
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under PTSD and other disorders. An important aspect to the remediation potential is how that
acute experience is shaped by intent and structure; in the clinical setting, that aspect is
represented as therapeutic intervention. The next section will elaborate on the practices of
psilocybin-assisted therapy and the research that has preceded the methods put forth by this
paper. In that, the pre-existing trial-based research, although not directed at PTSD, cushions a
PTSD-directed intervention by bearing the safety and efficacy of psilocybin-assisted therapy
when directed at other disorder; moreover, when that other disorder is chiefly depression, such
research is incredibly valuable for conceptualizing novel PTSD treatment.
Psilocybin-Assisted Therapy
Without randomized controlled trials on the topic, any human trials of psilocybin and
PTSD are somewhat uncharted territory. However, that process of testing needs to start
somewhere, and given the promising work that already exists for psilocybin, it seems appropriate
to start considering what psilocybin-assisted therapy for PTSD would look like. Outside of the
neurological, there is yet still treatment-specific research that guides its appearance.
In fear conditioning trials with mice, low doses of psilocybin were associated with
accelerated fear extinction after mice had been conditioned to expect a shock 30 seconds after a
tone; this conditioned state took the form of immobility for the 30 seconds after the tone,
whereas the unconditioned, or fear-extinguished, state took the form of wandering about the cage
after the tone. When compared with control and high-dose groups, the low-dose showed quicker
recovery of the unconditioned state (Catlow et al., 2013). As well, general trait changes could be
handy in the battle against PTSD. In a 6-month follow up with 19 participants treated for
treatment resistant depression with psilocybin-assisted therapy, analyses were conducted
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evaluating the presence of some experiential themes such as connectedness - meaning the
connection one has with senses, self, others, world, and/or spiritual principle - and acceptance meaning the foregoing of avoidance when faced with emotionally challenging thoughts or
experiences - based upon self-report. In that, participants reported significantly higher levels of
connectedness and acceptance when compared to participants’ previous experience in treatment
(i.e. SSRIs or talk therapy) (Watts et al., 2017). Historically, trauma-based disorder has shown a
theme of disconnection and avoidance, so improvements along those metrics might be productive
for both depression and PTSD.
Emotional dysregulation is another constant intrusion PTSD can have on daily life. Three
studies, described below, show how psilocybin can start to curb that negative emotional output.
After psilocybin administration on 25 healthy volunteers with no previous history of
hallucinogen use, it was found that, when presented with negative and neutral stimuli of
emotional imagery, amygdala reactivity was lowered on fMRI readings when compared to
control (Kraehenmann et al., 2015). In the acute phase of psilocybin effects, 33 participants were
evaluated for empathy capacity in hypothetical scenarios, in implicit computer-assisted measures,
and in self-report. Participants in the psilocybin condition showed significantly higher levels of
explicit and implicit empathy when compared to the placebo condition, regardless of the valence
of the stimuli (Pokorny et al., 2017). 379 participants in an online survey, conducted before and
after planned psilocybin administration, were presented with the Emotional Breakthrough
Inventory (EBI), which evaluates the capacity of participants to endeavor upon new emotional
thoughts, explorations, or struggles after psilocybin. Higher scores on the inventory were
dose-dependent and also associated with a therapeutic supplement (Roseman et al., 2019). This is
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all to say that psilocybin administration shows a positive relationship with stronger feelings of
empathy and with more comfortable emotional expression and sensation.
Clearly, there is a very real possibility that psilocybin can diminish the behavioral cruxes
of PTSD, but are these individual pieces of a treatment puzzle enough to take on the whole
disorder? Looking to some noteworthy architects of psilocybin-assisted therapy - Robin
Carhart-Harris and Roland Griffiths - there might be an answer. Carhart-Harris has crafted the
conceptual heart of psilocybin in its mechanisms during the therapeutic process; through
neurocognitive models, he has worked to render the classical psychedelic experience into its vital
components. Bounding off of his own conceptualization, he has pushed forward the treatment
approaches directing psilocybin toward depression; in focusing on set and setting, with blindfold
and music during administration and more hands-on integrative therapy after administration,
Carhart-Harris has established a standard for psilocybin treatment that has been carried forward
by other researchers (e.g. R. Carhart-Harris et al., 2021; R. Carhart-Harris et al., 2018; Gukasyan
et al., 2022; Yu et al., 2022). With a set standard that has shown some success in treating
depression, the barrier of orienting psilocybin towards other disorders is less disconcerting.
Similarly, the research of Roland Griffiths has helped to drive psilocybin to the point of an
adaptable therapy. Not only has he made contributions to the standards of psilocybin-assisted
therapy practice, using similar methods to Carhart-Harris but adapted for terminally-ill patients,
but he has also identified and curated an important therapeutic feature of psilocybin action: the
mystical-type experience (Griffiths et al., 2006, 2016). This psilocybin occasioned experience is
best described in the format of the Mystical Experience Questionnaire (MEQ) developed by
Griffiths et al. (2006); the mystical experience is marked by (1) inner unity - the integrity of the
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ego, (2) external unity - sense of connection or oneness with one’s environment, (3)
transcendence of time and space - loss of foundations for temporal and spatial grounding, (4)
ineffability and paradoxicality - the experience being indescribable and illogical, (5) sense of
sacredness - one’s amazement and spiritual quality being heightened, (6) noetic quality - the
experience being insightful and more meaningful than normal conscious living, (7) deeply-felt
positive mood - intense joy to the point of ecstasy.
These baffling experiences are often what participants struggle to describe after a trip, but
they have implications beyond pure research intrigue; higher scores on the mystical experience
questionnaire have been related to better treatment outcomes for anxiety, depression, and
addiction (Barrett & Griffiths, 2017). Therefore there is a real potency to the experiential and
indescribable. This anomaly in therapeutic processes speaks to the anomalous nature of
psilocybin as a treatment option; even if it does not directly target any individual disorder
through specific neural processes, it could provide such a profound experience to then empower
individuals to defy the patterns of disorder amid and following an entropic brain.
Introduction Insights
At this point socially, politically, and scientifically along the intersecting roads of
psilocybin and disorder, there is a rich opportunity to drive further. However, the roads are still
rife with obstacles and demand a cautious but driven approach. In the histories of psilocybin and
PTSD, the sociopolitical sphere overtook the narrative and direction of research. Psilocybin was
sidelined for decades, likely to the detriment of disordered and healthy individuals alike. PTSD is
still caught in the throes of debate, rendering it difficult to treat without a specific definition or
explanation for the disorder. One can only hope that history serves as a lesson learned for those
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involved in present research, but a new generation is upcoming and whole-heartedly joining the
effort. In light of that, the psychedelic movement must incorporate social conversation into the
fuel of its drive. Getting ahead of rumors (or mushrumors) and leading with research when
possible is the clearest path to proliferating psychedelic-assisted therapy; at no point should the
popular narrative accelerate past evidence to ground it. Although easier said than done, the
psychedelic community must practice control over its constituent members when possible to
limit any far-reaching, alienating speech. One must always be cognizant of the fact that all
speech and expression is political, and therefore all speech and expression in line with
psychedelics should be careful to avoid the poles of opinion and politics. Treatment should be
apolitical and accessible to all who need it; in the meantime, while federal regulation still
restricts psychedelics, the message of psychedelics should be a call for treatment and little more
until these substances are more palatable to the Western tongue.
Without available research from randomized controlled trials directing psilocybin
at PTSD, uncertainty in methodology and results is inevitable. But uncertainty does not preclude
strong evidence backing the safety of psilocybin as treatment, particularly when placed in the
proper clinical setting. The mechanisms of psychedelics are almost incomparable to other
treatment methods - even pharmaceutical ones. They redefine psychological treatment and
possibly the psychological concept of disorder. Treatment rarely lends patients such meaningful
experiences so consistently, in a way that psychedelics almost appear to circumvent the normal
expectations of pharmacotherapy; conventionally, the drug’s chemistry solely informs the
treatment outcome whereas with psychedelics, there is more stress placed on the experience of
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the drug and how that is integrated into normal living rather than just the interaction between
molecule and receptor.
The research ahead is purely a proposal. In no way were these methods conducted; in no
way was new data gathered to inform the results. It only serves to support the use of psilocybin
in a therapeutic context for a disorder as stubborn as PTSD. Additionally, it may provide a
template for possible future research, conducted by the proper, non-undergraduate researchers.
Most of all, it serves to inform those who are interested or ill-acquainted with the subject. Magic
mushrooms have far more capacity to help than to hurt; not only is that a personal opinion, but
the scientific method has verified and is constantly reverifying that claim. Skepticism is
appropriate and productive for all new things, and this paper does not assert that psilocybin will
be a cure-all for PTSD or otherwise, but one must avoid fear under the guise of skepticism. The
scientific method is reliable and inherently skeptical, so finding the line between errant claims
and scientific assertions is the necessary charge for every truly skeptical consumer. This paper
offers a strong foundation in good, peer-reviewed science and follows the pattern of
psychological research that is currently being conducted with psychedelics. That being said, it is
being offered by an author who is both an undergraduate and one rather passionate about that
research. Take everything with a grain of salt, but, very likely, this substance is not poisonous.
Methods
Participants and Team Members
Anticipating a medium to large effect size, the desired sample size will be at least 110
participants for comparing two arms of treatment along PTSD and depression symptom severity.
In taking a culturally-informed approach to psychedelic-assisted therapy, recruitment of the
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study’s participant pool and treatment team are two of the most important steps. Participants will
be recruited focusing on veterans coming off of service in Afghanistan in order to limit variation
in trauma type. Both participants and clinicians should be diverse in gender, race, sexual
orientation, and religious belief. For participants, the minimum diversity should reflect that of the
U.S. service members at large (~ 60% White, 15% Black, 15% Hispanic, 5% Asian, and 5%
Other; ~ 18% Women; Barroso, 2019). Additionally the treatment team should be diverse enough
so that every participant can be matched for race and gender by at least one monitor in the
treatment stage; ideally, monitors should come from different levels of clinical training and from
different backgrounds in therapeutic orientation as well. Before interacting with participants, all
team members (both therapy team and independent evaluators) will undergo diversity training
within the structure of Functional Analytic Psychotherapy (FAP), specifically directed at curbing
microaggressions and personal biases; this training provides a space to empathetically respond to
bias-based transgressions and turn them into learning opportunities (Tsai et al., 2009).
Clinicians actively seeing patients who served, as part of Operation Enduring Freedom
(OEF), within two years of the American evacuation from Afghanistan and have an index trauma
that is combat-related will be the focus in outreach; those clinicians will be identified through
USVA health care and contacted via email. They will then serve as the primary liaison for
recruitment. If both clinician and patient agree in favor of participation, the personal clinician
will then make an assessment of comorbid PTSD and Unipolar Major Depression diagnoses and
associated symptom severities. If the participant is included in the study, they will be asked to
taper off of selective serotonin reuptake inhibitors (SSRI) for at least five half-lives prior to
psilocybin administration for the sake of internal validity. Other contraindicated medications,
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such as antipsychotic medication, will be tapered as well. This decision is left up to the discretion
of the participant and the participant’s clinician; this study is concerned with experimental
validity, so common aspects of everyday treatment, like drug-drug interaction, will ideally be
controlled for in this trial. With the oversight of the personal clinicians, patients will be referred
to this study and, by preference, be contacted through email, paper mail, or text.
Following referral, participants will undergo screenings for mental and physical health.
An important aspect of the screening process is taking the time needed for participants to feel
heard and understand the steps of screening; this involves defining jargon terms and, sometimes,
using entirely different terminology to avoid alienating minority populations (Williams et al.,
2019). The former, mental health screening, will, by preference, be conducted over the phone or
video call by a team of eight independent mental health practitioners: they will exclude
individuals who have immediate family or personal history of psychosis or psychotic disorders,
history of serious suicide attempts, traumatic brain injury, bipolar disorder, eating disorder with
active purging, or any current substance-use disorder. These criteria have been delineated based
upon safety precautions specific to psilocybin’s neural mechanisms and generally controlling for
complications in treatment process (i.e. interactions between psilocybin and other substances,
having to fast pre-treatment or ingest psilocybin peri-treatment) .As well, participants are
expected to have a moderate degree of competency with the English Language. The mental
health practitioners will also conduct an assessment of PTSD and Unipolar Major Depression
measures to ensure consistency, greater reliability of measure, and establish a participant
baseline.
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The latter, physical health screening, will be conducted in-person by a team of eight
independent general practitioners, focusing on cardiovascular health (i.e. electrocardiogram for
heart rate, sphygmomanometer for blood pressure) and any glaring health issues that would take
up participant cognition during the trial; additionally, any MRI contraindications (i.e. metallic
implants) or positive pregnancy will result in exclusion. Baseline cardiovascular measures will be
taken at this stage. Following physical and mental health assessments, another exclusion
criterium will be previous habitual use of psychedelics (ten times or more) in an effort to control
for expectancy effects - the impacts that researcher’s behavior or participant’s preconceived
notions of the treatment can have on the treatment outcome. As the final part of screening,
participant demographic variables will be recorded through online surveys on Qualtrics.
Randomization
Speaking more to expectancy effects and participant priming, much attention will be
focused on blinding and removing bias. Blinding is a major issue in psychedelic research, as the
psychotropic effects of psychedelics can be distinguished from placebo rather easily by most
people; blinding of a participant falls apart when the participant can confidently guess that they
have received the treatment rather than placebo before procedural unblinding. This is even true
when an active placebo - a non-treatment drug that induces psychosomatic effects with little to
no therapeutic potential - is used for comparison. A drug like niacin has previously been used as
an active placebo in psilocybin trials as it gives the consumer a warm tingling sensation, but
masking still is not maintained due to the lack of hallucinogenic effects (Doblin, 1991).
Given that, the most optimal choice of treatment-placebo structure in the present study is
using a low dose of psilocybin as an active placebo; a low dose constitutes enough to begin the
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psychosomatic sensations of a psilocybin trip without inducing fully hallucinogenic effects. The
caveat is that this type of active placebo is predicated on the concept that its low dosage is not
enough to elicit therapeutic outcomes beyond those of inactive placebo. However, that has not
always shown to be true in research that has used low-dose psilocybin (10mg) as an active
placebo (e.g. Gasser et al., 2014). That is why this study will attempt a novel approach:
withholding from participants the number of dose levels in the trial in hopes that they will not
anticipate a placebo. The major roadblock to this approach is ethical in nature; it’s uncertain
whether this procedure violates informed consent, yet it might be necessary for proper blinding
(Muthukumaraswamy et al., 2021). In other words, this might just take some convincing of the
Institutional Review Board (IRB), but it is likely worth it.
After screening, participants are randomized into one of two treatment groups using the
demographic survey from Qualtrics. The control group, or low-dose group, receives two low
dose active placebos of psilocybin, with the lowest dose in the first session (3mg psilocybin/70kg
body weight) and a slightly higher dose in the second session (7mg/70kg). The treatment group,
or high-dose group, receives two therapeutic doses of psilocybin, lower in the first (22mg/70kg)
and higher in the second (27mg/70kg). Participants will be blind to condition as they are unaware
that there is more than one arm of the study.
Measures
Outcome Measures
Both diagnoses of Post-Traumatic Stress Disorder and Major Depressive Disorder will be
based on the Structured Clinical Interview for DSM-5 (SCID-5; First et al., 2016). Symptom
severity for the two will be based on the Clinician-Administered PTSD Scale for the DSM-5
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(CAPS-5; Weathers et al., 2018) and Beck-Depression Inventory - II (BDI-II; Beck et al., 1996)
respectively. These last two scales will be used as the study’s primary outcome measures for
evaluating psilocybin’s efficacy at addressing PTSD and MDD comorbidity. Given that they are
the primary outcome measures, they will be taken at baseline, before experimental sessions, after
experimental sessions, and at long-term follow-up.
The secondary outcome measures will focus on different aspects of the PTSD-depression
comorbidity. General quality of life will be assessed using the Quality of Life Inventory (QOLI;
Frisch et al., 1992). Mood will be measured using the Brunel Mood Scale (BRUMS; Terry et al.,
2003). Trait anxiety, or stable attention to negative emotions, will be measured using the
Spielberger’s Trait Anxiety Inventory (STAI; Spielberger, 1983). Avoidance will be measured
using the Brief Experiential Avoidance Questionnaire (BEAQ; Chawla & Ostafin, 2007; Gámez
et al., 2014). Suicidal ideation will be measured using the Suicidal Ideation Attributes Scale
(SIDAS; van Spijker et al., 2014). The measures above will also be taken at baseline, before and
after experimental sessions, and at long term follow-up. The Work and Social Adjustment Scale
(WSAS; Mundt et al., 2002) and Emotional Breakthrough Inventory (EBI; Roseman et al., 2019)
will only be taken at baseline and in follow-up.
Mystical experiences will be measured using the 43-item Mystical Experience
Questionnaire (MEQ43; Maclean et al., 2012). This self-report scale will be taken exclusively
after experimental sessions. This scale is being considered closely with the primary outcome
measures since mystical-type experiences have been implicated in therapeutic outcome
previously (Griffiths et al., 2006).
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Reliability Measures
In order to assess blinding integrity, a questionnaire will be conducted post-treatment
before and after debrief. The questions before debrief will evaluate whether participants would
recommend the treatment and whether the experience was what they expected it to be. After
debrief, the questions will evaluate whether they believed there was only one condition until
debrief, or whether, effectively, the deception was successful. Expectancy effects will be
measured through the Stanford Expectations of Treatment Scale (SETS; Younger et al., 2012),
this will be taken at baseline, the fourth preparatory session, and the fourth integration session.
Also, records will be kept of the ‘study culture’ and reported in debrief; how the study team and
participants interact is incredibly important for understanding contextual effects on treatment.
Generally, the culture should be framed by patience, clarity (when possible), care, and
professionalism. This will be recorded through a questionnaire at debrief for both study team and
participants.
Also measures will be taken to evaluate the subjective drug experience, somewhat like a
manipulation check. The two measures, taken after both experimental sessions, will be the
Hallucinogen Rating Scale (HRS; Strassman & Qualls, 1994) and the 5-Dimension Altered
States of Consciousness (5D-ASC; Dittrich, 1998). These will illuminate whether subjective
effects of the drug relate to therapeutic outcome and will evaluate the distinction in subjective
experience between control and treatment groups.
Safety Measures
Throughout the trial, adverse events of special interest (AESIs) will be monitored by
different members of the study team. The two main columns of these potential events are
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cardiovascular complications and suicidality. Diastolic and systolic blood pressure and heart rate
will be taken 10 minutes before and 30, 60, 90, 120, 180, 240, 300, and 360 minutes after
psilocybin administration in line with Griffiths et al. (2006) safety procedure; this will be
conducted by the general practitioners who also conducted screenings. Suicidal ideation will be
monitored through questioning, either by independent rater, monitor, or therapist, during
screening, preparatory sessions, experimental sessions, integration sessions, and follow-up. All
participants will be provided with a 24/7 phone number to call in case of serious suicidal ideation
or other mental health-related crisis, upon which a rotating member from the study facility will
be on-call and respond.
Procedure
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Recruitment
Clinicians all across the United States who accept USVA health care will be contacted
directly by phone. If the clinician shows interest in the study treatment, an email will be sent
providing more specifics about the study; if the clinician habitually sees viable candidates Afghanistan veterans with PTSD and depression - that clinician will reach out by email with a
patient recommendation. The recommended patient will then reach out by email to the study
team expressing interest which will initiate the screening process. After a correspondence has
been made from both patient and clinician, the clinician will be expected to fax over the results
from the SCID-5, CAPS-5, and BDI-II. For participants that have a combat-related trauma and
meet the criteria for comorbid PTSD and depression, the study’s mental and physical health
screenings will be cleared. Yet prior to screenings, participants will be provided with informed
consent in which the deception - there only being one arm of the study - will be elicited.
Participants’ baselines will be established for primary and secondary outcome measures, as well
as safety measures from the mental and physical health screenings. Whether the mental health
screening is over phone or video call is up to the participant, but that decision will be recorded
for covariation in outcome measures. In total, the mental health screening will be composed of a
description of the study - in line with the information provided with informed consent - and then
the SCID-5, CAPS-5, BDI-II, Quality Of Life Inventory, Brunel Mood Scale, Spielberger’s Trait
Anxiety Inventory, Brief Experiential Avoidance Questionnaire, and Suicidal Ideation Attributes
Scale. The physical health screening will be a general physical, asking and checking for any
outstanding injuries or trauma that could inhibit therapeutic outcomes, in addition to baseline
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blood pressure and heart rate measures with sphygmomanometer and electrocardiogram
respectively. After the screenings, participants - blind to groupings - will be randomized into one
of the two separate arms.
Set and Setting
The two separate groups will undergo identical procedures excluding dosing differences
amid experimental sessions. The next step in the procedure is developing the therapeutic alliance
and a comfortable study setting for participants throughout preparatory sessions. Each
participant’s sessions with the therapy team will take place in the same room throughout the
study. Rooms should be adapted to look homey with landscape paintings, warm lighting,
vegetation, and comfortable furniture. Only absolutely necessary medical equipment should be
present, otherwise the space should be devoid of clinical paraphernalia besides the clinicians
themselves. All sessions’ audio will be recorded to retroactively detect any thematic differences
between participant sessions and how that could relate to therapeutic outcomes; these recordings
are matched with an ID number designated from Qualtrics in the demographic survey for
participant de-identification.
The therapy teams are present in preparatory, experimental, integration, and follow-up
sessions. Each team is composed of two individuals: clinical and experiential monitor. The
former is a clinical psychologist, practiced with therapy for PTSD and depression, and the latter
is a monitor more experienced with altered states of consciousness, particularly psychedelics,
and dedicated to developing rapport with the participant. Expectations for the clinical monitor are
to maintain some structure of talk therapy in all sessions outside of the experimental; most
interaction will be between the participant and clinical monitor in preparatory and integration
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sessions. Also, the clinical monitor will conduct all peri-session measures except the Mystical
Experience Questionnaire, Hallucinogen Rating Scale, and the 5-Dimension Altered States of
Consciousness. The experiential monitor will be responsible for education and understanding
about the psychedelic experience; they will also attempt to provide reassurance throughout the
study. This monitor is more important for creating a comfortable space; one in which the
participant can feel free to ask any questions and express any concerns. In the experimental
session amid psychotropic effects, they will be the primary touchpoints back to reality.
Preparatory Sessions
There will be four preparatory sessions for every participant in the span of a week. The
first of those sessions will involve general introductions, discussion of previous therapy
experience, and education about psychedelic-use in therapeutic settings. This will involve a
description of what to expect in a psilocybin trip and how best to address the challenging
experiences that may come with it; generally, the message is to submit oneself to the experience.
Procedures of reassurance will be established (i.e. hand-holding and/or comforting words) as
well. The second of these sessions will focus on the experience of a participant’s comorbid
disorder in everyday life: what aspects of the quotidian are most hampered by disorder and what
does the participant most want to improve during the intervention. These goals can be small or
large, specific or general; the point is to direct the experimental sessions towards certain
cognition or behavior that is distressing. The third session is something of a quasi-experimental
session. By using holotropic breathwork for about 60 minutes, or the taking of deep, fast breaths
through the mouth, a state of altered consciousness can be induced. With the help of the
experiential monitor, this strenuous, but meditative breathing exercise will yield participants
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minor familiarity with the vulnerable state of a psychedelic trip. This session is also intended to
reinforce the therapeutic alliance precedent to the experimental sessions. Before the breathwork
session, the clinical monitor will conduct safety measures for suicidal ideation. Immediately
after, cardiovascular measures will be taken for safety and the 5-Dimension Altered States of
Consciousness will be taken for reliability. Participants will stay overnight at the study facility
and the next morning, there will be a quasi-integration session where the participant is asked
about the experience from the day before and whether any new insights have been gained from it
regarding disorder or everyday life; in this session, primary and secondary outcome measures
will be taken.
Experimental Sessions
One week following the fourth preparatory session, the first experimental session will
take place for both conditions. Participants will be asked to fast for about 10 hours prior to
psilocybin administration which is planned to start at 9AM. Before administration, safety
measures will be taken; cardiovascular measures will be taken at the aforementioned time
intervals throughout as well. Psilocybin will be administered in the form of a gelatin capsule with
a dose of 3mg/70kg for the control group and 22mg/70kg for the treatment group. Both
participants and monitors are blind to condition. During the 6-8 hours of psychoactive effects, the
experiential monitor must be acutely aware of any psychological distress that would warrant
reassurance or more rigorous intervention. Without any distress events during the session, the
experiential monitor will still be responsible for check-ins about every hour, asking broad,
subjective questions (i.e.

“where do you find yourself now?”). Participants will be under

blindfold, listening to a select playlist of music,and lying on a couch. If the participant needs
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anything, such as the bathroom, the experiential monitor will be responsible for assisting.
Generally, the session will be non-directive until the 8-hour mark, upon which the Mystical
Experience Questionnaire, Hallucinogen Rating Scale, and the 5-Dimension Altered States of
Consciousness will be conducted by the experiential monitor. Participants will be asked a few
general questions about the experience to ground them and will then be provided with food and
drink. Participants will stay overnight and undergo an integration session the following day.
Three weeks after the first experimental session, the second experimental session will occur
following the same procedure, but with 7mg/70kg and 27mg/70kg for the control and treatment
groups respectively.
Integration Sessions and Follow-up
The first integration session will take place in the morning after the first experimental
session. Both monitors will still be present, contributing equal parts to the integrative experience.
The experiential monitor will help the participant put the experience into words and develop a
logic around it. As well, the experiential monitor will draw attention to any specific thoughts or
insights mentioned by the participant amid the experimental session. The clinical monitor will
focus on any perceptual and/or symptom changes. Then, this monitor will try to orient the
experience towards everyday life, how it could apply to the improvements the participant initially
sought in treatment. Additionally, any new psilocybin-induced insights regarding the traumatic
experience(s) will be an important topic to touch on. The integration sessions will also be
important for identifying grounded behavioral changes to carry on after the trip; although
psilocybin might provide an acute window for cognitive and behavioral change, that can only be
carried forward with intention. The integration sessions are rather circumstantial, but can vary
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from turning challenging experiences during the trips into insights or even breakthroughs to just
visualizing the experiences through drawing or talking in order to evoke and recognize the
emotions felt during the trip. Regardless of these general guidelines, it will be up to the
participant to decide with whom to discuss the psilocybin experience out of the two; it can be
either or both, but the choice will be the participant’s. Three more integration sessions will take
place over the span of three weeks, from the first experimental session until the second. Four
integration sessions, using the above format, will also follow the second experimental session for
a total of eight. Primary and secondary outcome measures will be taken at the first, fourth, fifth,
and eighth integration sessions.
For follow-up, participants will return to the study facility and meet with both monitors
again, six months after the second experimental session. In follow-up, primary and secondary
outcome measures will be taken, now including the Work and Social Adjustment Scale and
Emotional Breakthrough Inventory. Participants will then undergo debriefing, which includes the
lowering of the mask and explanation of the study methods and participant groupings.
Participants will be asked blinding-integrity questions before and after debrief. They will also
provide subjective reflections on the psilocybin experiences and any marked lifestyle changes
that followed; these statements will be thematically coded to be correlated with other outcome
measures.
Predicted Results
All primary and secondary measures will be taken seven times in total, excluding the
Work and Social Adjustment Scale and Emotional Breakthrough Inventory which will only be
taken twice. The seven time points are baseline (at the start of the study), pre-experimental
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session one (at preparatory session four), post-experimental session one (at integration session
one), pre-experimental session two (at integration session four), post-experimental session two
(at integration session five), final study session (at integration session eight), and at follow-up
(six months after second experimental session). The Work and Social Adjustment Scale and
Emotional Breakthrough Inventory will be conducted exclusively at baseline and follow-up.
Primary Outcomes
Concerning the primary outcome measures, there will be a wealth of information to draw
from comparisons between groups at different time points of the study. A t-test for the difference
between two independent means will be conducted, comparing severity scores along the CAPS-5
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and BDI-II between control (low-dose) and experimental (high-dose) groups. From baseline to
the final study session, with an alpha of .05 and sample size of at least 110 participants, the t-test
is expected to find a marginally significant difference between groups for average CAPS-5 and
BDI-II scores, with lower symptom severity scores in the high-dose psilocybin group than the
low-dose. However, conducting the same t-test from baseline to post-experimental session one, it
is expected that there will be a largely significant difference between groups for both CAPS-5
and BDI-II due to more acute effects of the drug, with lower scores for the high-dose group . At
the six month follow-up, it is expected that there would be a near-significant difference between
groups, with lower scores for the high-dose group. More conservative estimates of CAPS-5
scores are provided than those of BDI-II scores due to the lack of available data for psilocybin
treatment with PTSD unlike psilocybin treatment with depression.
Secondary Outcomes
The secondary outcomes are evaluated both independently, for the varying impacts
psilocybin could have on participants outside of the purview of the primary outcome measures,
and jointly with primary outcome measures, for the influence those impacts could have on
symptom severity change or vice versa. It is expected that many of the secondary outcome
measures, similar to the primary outcome measures, will be dose-dependent; all measures are
considered, not only in relation to dosage, but also with scores on the Hallucinogen Rating Scale
and the 5-Dimension Altered States of Consciousness to ensure the manipulation was effective.
In that, it is expected that the high-dose group will show significantly higher pro-therapeutic
change from baseline on the Quality of Life Inventory, Brief Experiential Avoidance
Questionnaire, and Spielberger’s Trait Anxiety Inventory than the low-dose group at the
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post-experimental session one, post-experimental session two, and follow-up time points. The
pro-therapeutic change in the Brunel Mood Scale will be significantly higher in the high-dose
group than low-dose at the post-experimental session one time point, but not at post-experimental
session two nor follow-up. The Suicidal Ideation Attributes Scale will show greater
pro-therapeutic changes that do not reach significance in the high-dose group than the low-dose
at all time points. The Work and Social Adjustment Scale and Emotional Breakthrough Inventory
will show significantly greater pro-therapeutic changes from baseline to follow-up for the
high-dose groups as well. As for the Mystical Experience Questionnaire, it is expected that
higher scores will also be dose-dependent - so higher for the high-dose group than the low-dose.
In terms of correlation it is expected that higher scores on the Mystical Experience
Questionnaire relate to lower scores on the primary outcome measures and to pro-therapeutic
outcomes in secondary measures. Higher scores on the Quality of Life Inventory and Work and
Social Adjustment Scale will be related with lower primary outcome measures as well. Lower
scores Brief Experiential Avoidance questionnaire and Spielberger’s Trait Anxiety Inventory will
be related to lower scores specifically on the CAPS-5. Higher scores on the Brunel Mood Scale
and Emotional Breakthrough Inventory and lower scores on the Suicidal Attributes Scale will all
be related to lower scores specifically on the BDI-II. It is recommended that a regression analysis
is run to evaluate interacting effects (mediation and moderation) between different constructs
represented here.
Reliability Outcomes
Using the Stanford Expectations of Treatment Scale, it is expected that there will be no
significant difference in change between groups from baseline to pre-experimental session one,
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and pre-experimental session two. Study culture will be recorded for the sake of future research
rather than this study, evaluating whether it could interact with outcomes; therefore, no analyses
will be conducted for study culture in this study, only thematic coding of responses. Debrief
blinding questions will be considered subjectively by independent raters to understand whether
there was any doubt about study procedure and the singular treatment arm deception.
Discussion
This study proposal puts forth a comprehensive rationale and procedure for
psilocybin-assisted therapy directed at comorbid Post-Traumatic Stress Disorder and depression.
Given that no randomized controlled trials have yet been conducted concerning this topic, the
procedure is necessarily novel. There are aspects to this study that are relatively untested and
therefore leave room for uncertainty and flaws in internal validity, however that is an essential
risk in the research process. That being said, it is founded on other psychedelic-assisted therapy
methods that have been peer-reviewed and replicated multiple times. Beneath the methods lie a
wealth of literature on psilocybin, PTSD, and depression that provide a well-reasoned rationale
for research practice. This study will illuminate on the therapeutic potential of psilocybin for
PTSD in its whole spectrum of disorder.
Broad Takeaways
The overarching purpose of this proposal is to offer a path for one of the next steps in
psychedelic-assisted therapy research. Although PTSD with depression is fraught with
complications, psychedelics, specifically psilocybin and LSD, have shown promise in
remediating a variety of disorders with different symptom presentations. But beyond general
efficacy, psilocybin seems to specifically target some of the neural mechanisms related to PTSD
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and depression. If the appropriate precautions are taken in employing a treatment that is, for
some, perplexing and stigmatized, then the treatment for PTSD can very well be revolutionized.
Small steps informed by good practices will benefit all involved in the mental health field. This
proposal is one small step to eventually diversify the treatment options available to those
captured by disorder. By testing, for the first time, psilocybin directed at PTSD in a randomized
controlled trial, the substance’s treatment potential will be more clearly understood and possibly
refined. This study frames psilocybin-assisted therapy as effective at treating PTSD and
depression symptoms, particularly when administered at higher doses. Additionally, it posits that
the high-dose treatment, when compared with low-dose treatment, will significantly improve
quality of life, trait anxiety, avoidance, emotional development, and everyday life up to six
months after administration. More short term, psilocybin treatment generally will improve mood
and suicidal ideation.
Strengths
This study is directed at internal validity, and given its novelty, it will provide a
conservative proof of concept for future research. By limiting the participant population through
exclusion criteria of trauma type and comorbidity type, it makes it easier to assert that outcome
differences between groups and individual participants will be attributable to dosing, this study’s
manipulation, rather than other uncontrolled variables. As well, controlling for diet and
pharmaceutical intake allows the study to better assert that the psychosomatic changes
participants undergo will be due to psilocybin, and differences between groups will be due to
differential dosing. With a clear pathway from psilocybin to PTSD, any study outcomes will very
likely be caused by how and how much psilocybin is administered.
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Blinding, is therefore, an important strength to this study procedure. Since participants
will not be privy to different treatment arms, there should be no expectancy differential between
groups. Additionally, participant blinding integrity will be unlikely to falter given that
participants will not recognize that they are blinded. This is expected to show a marked
improvement in participant blinding from some other in vivo human psychedelic studies (e.g.
Carhart-Harris et al., 2021; Griffiths et al., 2016). Another novel strength of this study is its focus
on the therapeutic alliance. Factors such as diversity training, monitor-participant diversity
matching, the experiential monitor framework, and holotropic breathwork in the preparatory
stage are all expected to contribute to a strong alliance even prior to the study’s manipulation. A
strong alliance ensures the proper implementation of psilocybin-assisted therapy by reassuring
participants in a foreign experience and avoiding any undue anxiety (Johnson et al., 2008).
Novelty, in this study, is just as important as convention. Since it is founded on previous
work with psychedelics, facets of the procedure, such as setting formation, specific dosage, and
preparatory, experimental, and integration session conduct are built off of pre-existing, tested
structures of research. Although employing certain degrees of novelty, this study fits in well with
the literature that has already yielded promising results with psychedelics. Yet much of that
research with psychedelics, specifically around PTSD, has been done with MDMA. When
considering the value of this study, it is important to note that although breakthrough therapy
status for PTSD has been designated to MDMA, psilocybin could have benefits that MDMA
does not. Psilocybin, although less predictable and stable than MDMA, has greater capacity for
ego-dissolution, which this paper argues is an important component to treatment potential for
depression particularly, and PTSD potentially. As well, an argument against psilocybin is the
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potential it has to circumstantially induce anxiety which can be severely problematic for the
treatment of certain individuals with PTSD; however, this study dedicates extensive effort to
developing therapeutic alliance and establishing a comfortable setting for the sake of reducing
potential anxiety (Krediet et al., 2020). In a more ecological perspective, psilocybin has less
potential to cause adverse effects for individuals on SSRIs than MDMA, which supports
psilocybin’s direction toward depression comorbidity with PTSD. Psilocybin can be harnessed in
the right setting with the right procedures and the right people.
Limitations
In research studies, there tends to be something of a zero sum game between strengths
and limitations. That proves true in the current study as well, particularly in the dynamic between
internal and external validity. Where this study ensures that psilocybin administration, above all
else, will be the source of differences in outcome, it sacrifices some of the applicability this
manipulation will have to different populations in different settings. Sample restriction, such as
only including a specific, singular comorbidity of PTSD rather than its whole range of
comorbidities, only including a specific type of trauma, and only drawing from those who have
USVA healthcare, will inhibit how generalizable the results of this study will be. In the same
vein, necessitating an SSRI taper will limit how externally valid this study can be, considering
antidepressants such as SSRIs are a standard of treatment for PTSD and depression; if psilocybin
is to be implemented into standard treatment, it will have to take into account the drug-drug
interactions that will be controlled for in this study. For the average clinician addressing PTSD
and depression, factors like trauma type and other interacting disorders must be contended with
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in treatment. In that, this study will not provide a direct route from research to practice, but
begins a proof of concept to be reevaluated, improved, and, hopefully, verified by future research.
As with all other research done with psychedelics, study design warrants greater attention
to really address the relatively unique problems of expectancy and blinding. The design of this
study will make use of low-dose psilocybin as an active placebo to reduce differential expectancy
effects across groups and improve blinding integrity generally. However, with the benefits of that
design also come hindrances. Chiefly, as mentioned before, low-dose psilocybin might not be the
best placebo comparator considering it has the potential to yield large therapeutic effects. This
explains the predicted results of non-significant differences between groups on primary outcomes
at follow-up; both groups, even the control, may have substantial therapeutic improvement. This
maps onto work with low-dose psilocybin that shows not only near-equivalent improvement
between low and high doses, but, in rodent study, even greater improvement for low dose than
high dose on certain metrics, such as loss of fear conditioning (Catlow et al., 2013; Gasser et al.,
2014). The blinding of this study will be particularly directed at participant perspective, but a
downside is there will be the opportunity for blinding to falter among the study team, specifically
among the monitors. Given that the experiential monitor position is predicated on having
experience with altered states of consciousness, it will be expected that most of them will be able
to distinguish between the experiences of low and high doses. Monitors, therefore, are likely to
lose their blinding and recognize which condition participants are under. This may result in
differential treatment by monitors of the different study groups which may result in biased data.
There is a balance between blinding and comparison that future researchers must play with in
order to glean the most ‘true’ effects of psilocybin in treatment.
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Future Research
The research world of psychology still has a lot to learn from psilocybin. This study
attempts to push that research into a small portion of the vast territory that is yet unexplored. To
draw directly from the limitations of this study, there is a need for more externally valid and
blinding-conscious procedures. The next studies must focus on the real-world practice of therapy
and how this treatment could exist outside of a study setting where there are fewer variables that
are controlled for. As well, if it is the case that the low-dose condition is not significantly
distinguishable from the high-dose condition, the low-dose active placebo might not be the best
comparator despite its strengths in blinding. Using a non-psilocybin active placebo may be
possible if another study procedure is used; namely, a balanced placebo factorial design, in which
there are four conditions: the first where participants expect psilocybin and get psilocybin, the
second where participants expect psilocybin and get placebo, the third where participants expect
placebo and get placebo, and the fourth where participants expect placebo and get psilocybin.
The second and fourth conditions involve rather serious deception, so ethical considerations must
be made, but this is one feasible method to avoid using psilocybin active placebo
(Muthukumaraswamy et al., 2021). Also, in order to avoid monitor biasing, choosing monitors
who are less acquainted with psilocybin might prove important to maintaining a double-blind,
even if it is at the expense of the comfort provided by the experiential monitor.
Participant sample is something that should be explored extensively as well. Namely,
trauma type within the sample should be thoroughly investigated in how it interacts with the
treatment. It is unlikely that outcomes would be drastically different between trauma types, and
even less likely that it would perform worse in other trauma types considering military
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populations

experience

worse

treatment

outcomes

generally

(Straud et al., 2019).

Notwithstanding, trauma type is meaningful for symptom presentation and therefore meaningful
for direction of treatment. For example, combat trauma more often manifests in hyperarousal and
memory intrusion whereas sexual trauma shows higher rates of avoidance and negative mood
(Guina et al., 2018). Although these are just minutiae within a broad symptomatology, particulars
of symptom presentation are pivotal in formulating adaptable treatment. If it is the case that
different trauma types interact differently with this study’s methods, the methods should be
adjusted accordingly.
Moving away from the specific procedures of this study, looking more broadly at the
psychedelic-psychology field, there are two major regions of research that have not been
undertaken

in

randomized

controlled

trials:

different

types

of

psychotherapy

and

pre-experimental session psychedelic intervention. Addressing the former, most therapy that has
been employed alongside a study-based psychedelic administration tends to be non-directive:
participants are asked to sit blindfolded and are interacted with mostly for the sake of safety and
anxiety reduction (Krediet et al., 2020). Yet there is a whole gamut of psychotherapies that could
potentially supplement psychedelic-use more effectively than what is currently practiced. Take,
for example, cognitive processing therapy (CPT) for PTSD; with the addition of psilocybin, it
might be easier for participants to overcome stuck points and unhealthy cognitive patterns that
have developed since a trauma. Moreover, when compared to other psychotherapies, the shorter
timespan of cognitive processing therapy might align well with the track of psilocybin
administration. Yet, this raises a wealth of intriguing questions. When should psilocybin be
administered? In the midst of talk-therapy or a day beforehand? What dosage would work best
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for different therapies? Should psilocybin be used in the long term, in microdoses alongside
therapy, similar to SSRI-assisted therapies for depression? These questions do not yet have
answers, but the hope is that they eventually will.
The account of comfort within psychedelic-assisted therapy has already been touched on
conceptually and practically in this study; the components that curate a comfortable setting for
participants should be seen as equally valuable to the substance being administered. In an attempt
to reduce anxiety before a potentially life-changing experience, rooms are altered and music
playlists are created. These unusual variables can be rather consequential for therapeutic
outcomes and so they should be accounted for in procedure design (Johnson et al., 2008). Yet
comfort is a broad variable and can be targeted through other approaches than just interior design
and orchestral intervention. One of note is pre-experimental drug administration. By giving
participants a small dose of another psychedelic, such as LSD prior to the experimental session,
the participants are less likely to experience unfamiliarity-based anxiety during experimental
sessions (Krediet et al., 2020). As well, this has the capacity to improve the therapeutic alliance
prior to primary intervention. This study introduced holotropic breathwork as a novel stand-in for
such intervention, yet its success in inducing an altered state of consciousness is very much
dependent on one’s previous experience with meditation which often fluctuates greatly between
participants. Therefore, future research should consider a pre-experimental session of
hallucinogenic dosing with a substance comparable to the primary intervention in order to
improve participant comfort going into that intervention; this poses difficulties in the greater
funding and drug approval processes, but it should still be considered as an option.
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There is still so much that has not been employed in an experimental setting, often out of
an abundance of caution. That caution should not be forgone by any means, but in the case that
the current psychedelic-assisted therapy methods do not yield the consistently significant
pro-therapeutic results that they are currently, there are a variety of procedural changes that have
not yet been attempted and wield great therapeutic potential.
External Import
With high suicide rates and debilitation that halts many aspects of normal living, PTSD
has discouraging implications for the individual. With prevalence rates around 7% in the
American population, PTSD poses serious issues for the society. With no cessation of traumatic
events in sight, effective treatment remains ever-important. Psilocybin has already shown
significant therapeutic potential for a wide range of the disordered experience including
depression, anxiety, addiction, and obsessive compulsive disorder (Bogenschutz et al., 2015;
Carhart-Harris et al., 2016; Castro Santos & Gama Marques, 2021; Johnson et al., 2014; Moreno
et al., 2006). Further, psilocybin shows low abuse potential, generally minimal safety concerns,
and positive outcomes for individuals outside of disorder (Gukasyan et al., 2022; Johnson et al.,
2018; Rucker et al., 2022). With promising evidence, the research will hopefully continue and
contribute to the betterment of people’s lives. Substances like psilocybin - psychedelics,
hallucinogens - defy current Western standards for treatment and medicine. There is a wealth of
information to be drawn from the eclectic molecules; whether that is information about the world
at large or about how we conceptualize our minds remains to be seen. There is a possibility that
psilocybin could alter the way the West considers treatment. Or maybe disorder could be founded
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in a singular pattern of cognition that psychedelics help to disrupt (Pollan, 2018). There is no
telling at this stage, but research is a helpful tool to figure that out.
This study’s focal point is veterans and their combat-related trauma. As already
discussed, they have been chosen not only to control for trauma type, but to address a population
that is systematically ignored by the government that haphazardly disordered and forgot about
them. As shown in the history, war has propelled much of the present understanding of PTSD,
but that history was also dominated by rhetoric of malingering and denial. The United States has
consistently fallen short of providing the appropriate mental health treatment for those exposed
to combat. Since veterans are about two times as likely to develop PTSD, this is a serious
problem that rests at the feet of the U.S. government (Friedman, 2019). When the impoverished
and disenfranchised of this country are funneled into an overfunded military industrial complex
in which they experience repeated traumas amid imperialist campaigns, the responsibility of
treatment does not fall on those caught in the cogs, but the ones running the machine. Psilocybin
and other psychedelics have shown promise for remediating some of the veteran’s mental and
existential strife. By funding psychedelic research and providing easy access to the treatment for
all who need it, the structures can begin to heal some of the damage they have done.
However, that has not yet been realized. With all psychedelics, other than ketamine
(licensed as esketamine for treatment-resistant depression) still listed by the FDA as Schedule 1,
veterans and other PTSD-affected populations are left to work with inconsistent treatment. Given
the treatment potential that psychedelics have shown for disorder, veterans have taken it unto
themselves to seek out the treatment abroad, footing rather expensive travel bills for ayahuasca
treatment that their own country will not provide (Israel, 2017). If this country professes to be
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concerned with mental health, helping specifically-targeted populations is a good start. Yet in no
way should effective treatment ever justify the initial harm done. Actively distressed veterans are
victims of a system that has failed them. This distress has created an outcry directed at the
system. Even if proper treatment responds to and addresses the distress, there still remains a
systemic problem. Confronting PTSD starts with prevention, not treatment. For the veteran
population, that means avoiding war where possible; in recent years, in the United States,
avoiding war has been more than possible, just not profitable. Psilocybin should be used to
improve lives where it can, but it should not be used as a crutch for a failed system. This study
advocates for harm reduction; systemic change for the sake of harm prevention must manifest
alongside the treatments that offer harm remediation. Although this study is fighting for the
responsive side to harm reduction, there is a whole other battle to be fought for prevention, and it
starts with reevaluating the systems that are.
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Appendix A

INFORMED CONSENT AGREEMENT
Study Title: Tripping over Trauma: A Proposal of Psilocybin-Assisted Therapy for
Comorbid Post-Traumatic Stress Disorder and Depression.
Principal investigator: Liam Gomez
Background. The goal of this study is to examine the therapeutic potential of
psilocybin-assisted therapy for comorbid PTSD and depression.
What you will do in this study. You will consume the classical psychedelic,
psilocybin, twice in the form of gelatin capsules. This will be supplemented by
different stages of talk therapy primarily focused on traumatic experience
recollection, everyday PTSD/depression symptoms, the psychedelic experience,
and any interaction between the psychedelics and recollection or symptoms
following treatment. Additionally, you will also be asked to respond to a series of
different measures, either self-reported or administered by site staff.
Study time and location. The study will be conducted at John Hopkins University,
specifically the John Hopkins Bayview Medical Center. The primary study sessions
should take about two months from recruitment to conclusion. This is divided up
into one screening, four preparatory sessions, two experimental sessions, and eight
integration sessions. There will be a six-month follow-up session as well.
Risks and benefits. Since there will be therapy directed at trauma recollection,
there is a chance for major distress. As well, those unfamiliar with psilocybin can
experience anxiety amid the psychotropic effects. There is a small chance of
psychosis or lasting perceptual changes from psilocybin intake. Throughout the
study, monitors will be present to aid through any mental or physical distress. In
addition to the monitors, you will have access to a 24-hour hotline if you are
experiencing any distress outside of the sessions. This study has the potential
benefit to promote recovery in individuals with PTSD and depression, by reducing
distressing symptoms or improving quality of life. This study will also provide
participants with educational benefits on psychedelic function and treatment, with
additional information on non-traditional treatment forms (i.e. holotropic
breathwork).
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Compensation. All participants will be monetarily compensated for their time.
Participants will be given $10 for every preparatory and integration session, as well
as the follow-up session. For experimental sessions, participants will be paid $15.
Your rights as a participant. Participation in this study is completely voluntary.
You may withdraw at any time with no questions asked, and no penalty;
participants will be provided with the remainder of their session-based
compensation in the case of withdrawal.
Confidentiality. All measures and audio recordings will be assigned to a
participant ID, removed from any personal identifiers. There will be no record of
personal identifiers in published materials.
Contact. If you have any questions regarding this study please do not hesitate to
ask now or contact Liam Gomez, email: lg9312@bard.edu. If you have any
questions regarding participant rights please contact the Institutional Review
Board, email: irb@bard.edu.
Consent. By signing below, I am agreeing to participate in this study and affirm
that I am at least 18 years old. I am agreeing to be contacted via phone or email to
schedule times to participate. I affirm that the research has been explained to me
and that I am participating voluntarily, and may withdraw at any time.

__________________________________
Participant name (printed)
__________________________________
Participant signature

____________
Date

__________________________________
Researcher signature

____________
Date
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Appendix B

DEBRIEF
Study title: Tripping over Trauma: A Proposal of Psilocybin-Assisted Therapy for
Comorbid Post-Traumatic Stress Disorder and Depression.
Principal Investigator: Liam Gomez
Purpose of the study. The purpose of this study is to determine whether
psilocybin-assisted therapy was effective at treating PTSD and depression
symptoms. This was measured between two different groups: a low-dose group and
a high-dose group. It was hypothesized that the high-dose group would show
greater reductions in symptoms and better general treatment outcomes than the
low-dose group.
Deception. You were not informed that there were two groupings of participants.
This meant that one group, without knowing it, was given a higher dose with a
hypothesis that it would show greater therapeutic benefit than the lower dose
group. This deception was done so that you would not attempt to guess which
group you were in based on how intense the psilocybin experience was. If one is
aware of what group one is in, there is the potential for that to influence the study
results beyond just the treatment. This deception allows a more controlled
comparison of the two groups.
Contact. If you have any questions regarding this study please do not hesitate to
ask now or contact Liam Gomez, email: lg9312@bard.edu. If you have any
questions regarding participant rights please contact the Institutional Review
Board, email: irb@bard.edu.
Support. If you experienced absolutely any distress from this study please contact
the designated contact monitor ([phone number] and [email]). For any additional
support please call the 24-hour confidential crisis support, Veterans Crisis Line, at
1-800-273-8255, text 838255, or chat online at
https://www.veteranscrisisline.net/get-help-now/chat/.
Additional information. For any additional information or assistance regarding
PTSD and depression, please refer to your personal clinician or the resources at
https://www.ptsd.va.gov/.
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Appendix C

BUDGET PLAN
Psilocybin supply. With an average cost of about $7 per milligram of synthetic
psilocybin and a desired sample size of 110 participants, the cost for two sessions
for every participant across the two different dosage groupings will be
approximately $23,000.
Participant compensation. Between the $10 for every preparatory, integration,
and follow-up session and $15 for every experimental session, compensation for
all 110 participants will require approximately $18,000.
Study team compensation. The independent raters responsible for conducting
mental and physical health screenings will be paid $18 per hour during screening,
in which time spans will greatly fluctuate between individual screenings so an
estimate is difficult to determine for each individual. Approximately $6,000 should
be allocated for screenings, although that may be subject to change. The clinical
monitor will be paid at $22 per hour, the experiential monitor will be paid at $20
per hour, and the general practitioner present during sessions to take safety
measures and intervene in the case of adverse events will be paid at $18 per hour.
In total, this will cost approximately $204,600. From screening to follow-up, study
team compensation will be approximately $210,600.
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Appendix D

STATISTICAL PLAN
Confirmatory analysis. The primary analysis that will be conducted to evaluate
the efficacy of psilocybin-assisted therapy on PTSD and depression symptom
reduction will be a two-tailed t-test for the difference between two independent
means with an alpha of .05. This will be conducted along the primary outcome
measures - the CAPS-5 and BDI-II - attempting to detect a difference between the
scores of the low-dose group and the high-dose group from baseline to four
different time points of the study: post-experimental session one, post-experimental
session two, final study session, and follow-up. For all secondary outcome
measures, a two-tailed t-test for the difference between two independent means
with an alpha of .05 will be used, comparing the change in measure score from
baseline to the aforementioned time points between the two different participant
groups.
Exploratory analysis. This analysis incorporates the secondary outcome measures
and reliability measures (Quality Of Life Inventory, Brunel Mood Scale,
Spielberger’s Trait Anxiety Inventory, Brief Experiential Avoidance Questionnaire,
Suicidal Ideation Attributes Scale, Mystical Experience Questionnaire, Work and
Social Adjustment Scale, Emotional Breakthrough Inventory, Hallucinogen Rating
Scale, and the 5-Dimension Altered States of Consciousness). Using a correlation
matrix with Pearson’s r correlation coefficient grouped by dosage groupings, any
significant relationships between measures will be detected. These measure scores
will also be correlated with the primary outcome measure scores at different time
points throughout the study. Primary and secondary outcome measures will be
grouped by reliability measures scores to detect any failure in manipulation, or
differences based upon psilocybin’s reported psychotropic effects. As well, primary
and secondary outcome measures will be considered in relation to demographic
variables.
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Appendix E

SCALES AND MEASURES
*Measures without available .pdfs are described in text below*

Quality of Life Inventory. This is a 32-item scale with three-point rating scale for
importance, and six-point rating scale for satisfaction. Its denoted constructs are:
Health, Self-Esteem, Goals and Values, Money, Work, Play, Learning, Creativity,
Helping, and Love, as well as Friends, Children, Relatives, Home, Neighborhood,
Community, and Overall Well-being.
Brief Experiential Avoidance Questionnaire. This is a 15-item scale with a
six-point rating scale. The prompts cover a range of avoidance: of pain, of
uneasiness, of effort, of upset, of unpleasantness, of discomfort, of emotions, of
painful emotions, of feelings, of bad feelings, of upsetting feelings, of fear/anxiety,
of unpleasant memories, and of doubts.
Brunel Mood Scale. This is a 24-item scale that asks respondents to rate a list of
adjectives on a five-point Likert scale. There are six affective mood dimensions of
the scale, all with different subscale items: Anger: annoyed, bitter, angry,
bad-tempered; Confusion: confused, muddled, mixed-up, uncertain; Depression:
depressed, downhearted, unhappy, miserable; Fatigue: worn out, exhausted, sleepy,
tired; Tension: panicky, anxious, worried, nervous; Vigor: lively, energetic, active,
alert.
Emotional Breakthrough Inventory. This is a six-item scale, with ratings on a
visual analogue scale from 0-100.The items are outlined below (Roseman et al.,
2019):

Hallucinogen Rating Scale. This is a 71-item scale with each item scored from
0-4 on the degree to which an item was experienced. The items are grouped
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according to: Somaesthesia: somatic effects; Affect: emotion and affect; Volition:
capacity to willfully interact with the self or environment; Cognition: alterations in
thought processes or content; Perception:change in perceptual experience;
Intensity: strength of the overall experience.
*5D-ASC, BDI-II, CAPS-5, MEQ43, SETS, SIDAS, STAI, and WSAS below*

…
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